CURRICULUM VITAE
Mustafa F. Lokhandwala, Ph.D.
EDUCATION
Degree
Year
Institution
Field
B.Pharm
1966
L.M.College of Pharmacy
Ahmedabad, India
Pharmacy
M.S.
l968
Columbia University
New York, New York
Pharmacology
Ph.D.
1975
University of Houston
Houston, Texas
Pharmacology
PROFESSIONAL APPOINTMENTS
Title
Institution
Dates
Dean
College of Pharmacy
University of Houston
2008-2009
Director
Heart and Kidney Institute
University of Houston
2006-present
Executive Vice Dean
For Research
College of Pharmacy
University of Houston
2003-present
Dean
College of Pharmacy
University of Houston
1991-2002
Professor
Department of Pharmacology
University of Houston
1989-present
Chairman
Department of Pharmacology
University of Houston
1980-1991
Associate Professor
Department of Pharmacology
University of Houston
1981-1989
Assistant Professor
Department of Pharmacology
University of Houston
1975-1981
Research Assistant
Department of Pharmacology
Columbia University/Ciba-Geigy
New York and Tuckhoe, N.Y.
1970-1971
OTHER APPOINTMENTS
Adjunct Professor
Hypertension & Clinical Pharmacology
Baylor College of Medicine
Houston, Texas
1989-present
Adjunct Associate
Professor
Hypertension & Clinical Pharmacology
Baylor College of Medicine
Houston, Texas
1986-1989
Visiting Professor
University of Rome
Rome, Italy
September, 1989
Visiting Professor
The Third Military Medical University
Chongqing, P.R.China
March, 2007
RESEARCH INTERESTS, TRAINING AND TECHNIQUES
Cardiovascular and Renal Pharmacology
Hypertension and Antihypertensive Drug Mechanisms
Central and peripheral control of the cardiovascular and renal function
Role of oxidative stress in hypertension, diabetes and aging
- receptor-G protein coupling
- drug responsiveness
- antioxidant supplementation
- redox imbalance and role of transcription factors
- activators of antioxidant responsive elements
Dopamine, Dopamine Receptor Agonists and Cardiovascular Function
Dopamine receptor function in obesity, diabetes, hypertension and aging
Dopamine receptor mediated cellular signalling mechanisms in the proximal tubule
Role of kidney dopamine in sodium balance and control of blood pressure
Oxidative stress and D1 receptor signal transduction in the kidney
Research Techniques
Measurements of inflammatory, reactive oxygen species and several biomarkers in
hypertension, aging and diabetes
In vivo measurements of cardiac function including output, contractility
Measurements of venous return and vascylar rsistance in various beds
Sympathetic nerve stimulation induced changes in cardiac and renal function
Measurements of renal function including renal plasma flow, glomerular filtration
rate, sodium excretion, pressure natriuresis relationships
2
Cardiovascular and renal responses to drugs and other maneuvers in models of
diabetes, hypertension and aging.
.
Research Accomplishments
Identification of presynaptic dopamine receptors on sympathetic nerve terminals under
in vivo conditions and the demonstration that activation of these receptors was
responsible, at least in part for the vasodilator action of dopamine.
Demonstration of the uncoupling of D1 receptor in proximal tubule from the G-protein
in hypertension and in aging
Hyperglycemia and hyperinsulinemia contribute to receptor-G protein uncoupling in
type I and type II diabetes, respectively.
Improvement of insulin sensitivity in diabetic rats with drug therapy restores D1
receptor-G protein coupling and renal responsiveness to dopamine.
The mechanism by which oxidative stress and inflammation contribute to various
diseases: Studies on the role of NFkB, Nrf2 and Phase II antioxidant enzymes.
AWARDS & HONORS
University of Houston chapter of Sigma Xi, The Scientific Research Society’s Research
Excellence Award for 1993.
Individual Educational Excellence Award, Texas Pharmacy Foundation, 2000
Robert A. Boblitt Rho Chi Lectutre, 2004
TEACHING EXPERIENCE
Pharmacology
Principles of Drug Action
Hypertension/Antihypertensive Agents
Angina/Antianginal Agents
Graduate Courses
Adrenergic/Cholinergic Pharmacology
Cardiovascular pharmacology
Cardiovascular research techniques
Advances in renal pharmacology
GRADUATE STUDENTS
3
A. A. Martinez,
Dissertation title:
Ph.D.
(l980)
Involvement of sympathetic nervous system in the cardiovascular
actions of 5-hydroxytryptamine
G. J. Hom,
Thesis title:
M.S.
(l980)
Presynaptic inhibition of sympathetic nervous system by adenosine:
physiological & pharmacological implications
S. J. Augustine,
Thesis title
M.S.
(l98l)
Characteristics and mechanisms of clonidine withdrawal in
normotensive and hypertensive rats
A.T. Hamed,
Dissertation title:
Ph.D.
(l98l)
Pharmacological significance of cardiovascular dopamine receptors
R. J. Barrett,
Dissertation title:
Ph.D.
(l982)
Role of sympathetic nervous system dopamine receptors in the
cardiovascular actions of lergotrile and pergolide
E. J. Peter,
Thesis title:
M.S.
(l984)
Pharmacological analysis of the actions of calcium entry blockers
felodipine, nifedipine and verapamil: Interactions with pre and
postsynaptic alpha adrenoceptors.
S. Sengupta,
Thesis title:
M.S.
(1985)
Pharmacological characterization of the cardiovascular actions of
dopamine receptor agonists, fenoldopam and quinpirole in rats.
M. H. Sabouni,
Dissertation title:
Ph.D.
(1986)
Pharmacological characterization of dopamine receptors in the
sympathetic ganglia
G. Kavukondala,
Thesis title:
M.S.
(1986)
The role of Na+-K+-ATPase in the regulation of sympathetic neuroeffector function in the isolated perfused rat kidney
S. S. Hegde,
Dissertation title:
Ph.D.
(1990)
Renal dopamine in the regulation of sodium and water excretion during
acute volume expansion
S. J. Vyas,
Dissertation title:
Ph.D.
(1992)
Involvement of tubular DA-1 receptors in the natriuretic and diuretic
responses to dopamine and dopexamine: Role of Phospholipase-C in
cellular signaling events
C. J. Chen, M.D.
Dissertation title:
Ph.D.
(1992)
Dopamine receptor- coupled cellular signaling mechanisms in renal
proximal tubules of spontaneously hypertensive rats
S. Gopalakrishnan, M.S.
(1994)
Thesis title:
Alpha-1 adrenoceptors in the renal proximal tubules: Characterization
and cellular signaling mechnisms
4
U. Venkatakrishnan, M.S.
(1994)
Thesis title:
The role of nitric oxide in the diuretic and natriuretic responses to
dopamine-1 receptor activation
V. Kansra,
Thesis title:
M.S.
(1995)
Dopamine stimulates protein kinase C activity in normotensive but not
in hypertensive rats
M. Bharatula,
Thesis title:
M.S.
(1996)
Characterization of Angiotensin Type I (AT1) Receptor Subtypes in the
Biphasic Effect of Angiotensin II on Renal Proximal Tubular Sodium
Potassium ATPase
V. Kansra,
Dissertation title:
Ph.D.
(1997)
Renal dopamine receptor signaling mechanisms in Fisher 344 old rats
S. Beheray,
Dissertation title:
Ph.D.
(1999)
Age related alterations in dopamine receptor-mediated signaling
pathways in renal proximal tubules
M. Becker
M.S.
(1999)
Alterations in angiotensin II receptor mediated signaling pathways in
the renal proximal tubules of obese Zucker hypertensive rats
V. Narkar
Dissertation title:
Ph.D. (2002)
Dopamine D2 receptor signaling and function in renal proximal
tubules
M. Menezes
Thesis title:
M.S.
(2002)
Alterations in dopamine D2-like receptor signaling mechanisms in
renal proximal tubules of Fischer 344 rats.
M. Trivedi
Pharm.D. / Ph.D. (2004)
Renal dopamine receptor dysfunction in obese Zucker rats.
A. Marwaha
Ph.D. (2005)
Renal dopamine D1 receptor function in hyperglycemia associated
oxidative stress
R. Fardoun
Pharm.D. / Ph.D. (2006)
Cellular mechanisms of oxidative stress-induced defective renal
dopamine D1 receptor function
A. B. Muhammad
Ph.D. (2010)
Effect of exercise and caloric restriction on renal dopamine D1
receptor function in obese Zucker rats.
L. George
Pharm.D. / Ph.D. (2010)
Mechanism of exercize-mediated restoration of renal dopamine D1
receptor function in aging.
5
S. Bhatt
Ph.D. (2011)
Vascular oxidative stress in hyoertension
G. Chough
Ph.D. (2011)
Role of age-associated oxidative stress in altered renal D1 and AT1
receptor fuhctions and hypertension.
A. Javedhkar
Ph.D. (2011)
Oxidative stress and renal AT1 receptor function during hypertension.
POSTDOCTORAL FELLOWS AND RESEARCH FACULTY
Dr. R. D. Ekas
Dr. D. C. Eikenburg
Dr. A. L. Jadhav
Dr. S. Tachikawa
Dr. J. L. Montastruc
Dr. H. O. Watkins
Dr. A. F. Ansari
Dr. G. D. Adjei
Dr. A. T. Hamed
Dr. M. L. DeFeo
Dr. T. Sakamoto
Dr. A. T. Hamed
Dr. C. J. Chen
Dr. T. Hussain
Dr. M. Asghar
Dr. L. Zhang
Dr. A. Banday
Dr. A Marwaha
1978-1982
1979-1981
1981-1988
1981-1982
1982
1982-1990
1984-1985
1984
1985
1986-1987
1991-1992
1992-1993
1992-1994
1995-2001
1999-present
2001-2002
2001-present
2005-2006
6
GRANT & CONTRACTS
Studies on the mechanisms of antihypertensive action of various beta adrenergic
blocking agents
From: New Research Opportunities Program
University of Houston
$4,518; 1/1/76 to l2/31/76
Studies on the functional role of presynaptic beta adrenergic receptor mechanism in
sympathetic neurtoransmission
From: Pharmaceutical Manufacturers Association Foundation
Washington, DC
$10,000; 1/1/77 to 12/31/78
Vascular reactivity in experimental hypertension
From: American Heart Association; Texas Affiliate, Inc.
Austin, Texas
$12,685; 7/l/78 to 6/30/79
Presynaptic regulatory mechanisms in hypertension
From: National Heart, Lung and Blood Institute; National Institutes of Health
Bethesda, MD
$194,242; 7/l/78 to l2/31/82
The role of sympathetic nervous system in the cardiovascular actions of dopaminergic
agents
From: Eli Lilly & Co.
Indianapolis, Indiana
$7,l75; 7/1/81 to 6/30/84
Studies on the role of central nervous system in the cardiovascular actions of pergolide
From: Limited Grants-in-Aid Program
University of Houston-University Park
$600; 6/1/82 to 8/31/82
7
Presynaptic dopamine receptors and sympathetic function
From: National Heart, Lung & Blood Institute; National Institutes of Health
Bethesda, MD
$146,692; 8/l/80 to 7/31/85
Cardiovascular actions of LY-l4l865
From: Eli Lilly & Co.
Indianapolis, Indiana
$3,850; 7/1/84 to 6/30/8
Cardiovascular dopamine pharmacology
From: Smith Kline & French Laboratories
Philadelphia, PA
$4,000; 4/1/85 to 3/31/86
Travel Award to attend the Asian Congress of Pharmacology, New Delhi, India
From: Provost's Office
University of Houston-University Park
$1,000; 1/1/85 to 3/31/85
Program for Stimulation of Research Careers in the Pharmaceutical Sciences
From: AACP
Bethesda, Maryland
$13,475; 4/1/85 to 3/31/86
Symposium on Dopaminergic Systems in Hypertension
Gent, Belgium. September 8-9, 1986
From: Smith Kline and French Laboratories,Philadelphia, PA
$6,500
From: Eli Lilly and Company, Indianapolis, Indiana
$750
From: Rhone Poulenc Sante, Paris, France
$1,000
From: Abbott Laboratories,Chicago, Illinois
$500
Pathogenesis of Hypertension
From: NHLBI Minority School Faculty Development Award for Dr. Arun L. Jadhav
$4,500; 9/1/85 to 8/30/90
8
Directed Research Career Development Program for Pharmacy Students
From: AACP
Bethesda, Maryland
$20,130; 5/1/86 to 8/31/87
Evaluation of dopamine receptor function in spontaneously hypertensive rats following
chronic treatment with agonists
From: Eli Lilly & Co.
Indianapolis, Indiana
$6,468; 1/1/87 to 12/31/88
Role of Dopamine in Urinary Sodium Excretion
From: University of Houston/BRSG
$5,000; 4/l/87 to 3/31/88
Cardiovascular Effects of Liposomal Encapsulated PGE-1 in Rats
From: Liposome Technology, Inc.
Menlo Park, CA
$5,000; 4/1/88 to 3/31/89
Selective Dopamine Receptor Agonists in the Treatment of Genetic Hypertension in
Rats
From: NHLBI Minority School Faculty Development Award for Dr. Halcyon O. Watkins
$146,305; 4/1/88 to 3/31/93
Autoradiographic, Biochemical and Pharmacological Studies on the Dopamine-1
Receptors in the Cardiovascular System with Fenoldopam
From: Smith Kline and French Laboratories
King of Prussia, PA
$10,000; 6/1/88 to 5/31/89
Role of Kidney Dopamine in the Natriuretic Response to Acute Volume Expansion:
Potential Interactions with ANF (Schering Predoctoral Fellowship for S. S. Hegde)
From: Schering Corporation
Bloomfield, NJ
$32,000; 9/1/88 to 8/31/90
Characterization of the Renal Effects of Dopexamine
From: Fisons Pharmaceuticals
Leicestershire, England
$47,000; 1/1/89 to 12/31/90
Biochemical Neuropharmacology
9
From: Baylor College of Medicine
Houston, TX
$25,000; 1/1/89 to 12/31/92
Autoradiographic and Functional Studies on Dopexamine
From: Fisons Pharmaceuticals
Leicestershire, England
$25,000; 2/1/89 to 1/31/91
Effects of Dopexamine on Myocardial Contractility in Hemorrhagic Shock
From: Fisons Pharmaceuticals
Leicestershire, England
$60,000; 1/1/90 to 12/31/91
Biochemical Studies on Dopexamine
From: Fisons Pharmaceuticals
Leicestershire, England
$12,000; 1/1/90 to 12/31/91
Symposium on Significance of Peripheral Dopaminergic System in Cardiovascular and
Renal Function. Essen, West Germany, July 8-10, 1990
From: Fisons plc, Leicestershire, England
$15,000
From: Simes Cardiovascular Resarch Center, Milan, Italy
$10,000
From: E. Merck & Co., West Germany
$3,000
From: Syntex Research
$1,000
From: Smith Kline & French Laboratories, Swedeland, PA
$500
Autoradiographic Localization of Dopexamine Binding in the Human Cardiovascular
System
From: Fisons Pharmaceuticals
Leicestershire, England
$54,000; 1/1/90 to 12/31/91
Schering-Plough Support for Predoctoral Training Program in Pharmacology
From: Schering Corporation
10
Bloomfield, NJ
$15,000; 9/1/90 to 8/31/91
Interactions Between Norepinephrine-Dopexamine in Affecting Renal Function
From: Fisons Pharmaceuticals
Leicestershire, England
$10,000; 1/1/91 to 12/31/91
Effect of Dopexamine on Mesenteric Circulation During Hemorrhagic Shock
From: Fisons Pharmaceuticals
Leicestershire, England
$60,000; 1/1/91 to 12/31/92
Autoradiographic Localization of Dopexamine Binding in the Human Intestinal Vessels
From: Fisons Pharmaceuticals
Leicestershire, England
$40,000; 1/1/91 to 12/31/92
Schering-Plough Support for Predoctoral Trainee in Pharmacology
From: Schering Corporation
Bloomfield, NJ
$55,000; 9/1/91 to 8/31/95
Influence of Bradykinin Receptor Antagonist on the Cardiovascular and Renal Effects
of Angiotensin II Receptor Antagonist and Ramipril
From: Hoechst-Roussel Pharmaceuticals, Inc.
Sommerville, NJ
$30,000; 3/1/92 to 2/28/93
Influence of Dopexamine on Cardiovascular Toxicity Produced by Xanthine and
Xanthine Oxidase
From: Fisons Pharmaceuticals
Leicestershire, England
$25,000; 4/1/92 to 3/31/93
Influence of Angiotensin Converting Enzyme Inhibition and Receptor Blockade on the
Renal Effects of Fenoldopam
From: Merck Sharp & Dohme Research Laboratories
West Point, PA
$20,000; 11/1/92 to 10/31/93
Provision of Pharmaceutical Care in Texas Prisons
From: Texas Department of Criminal Justice,Austin, TX
$1,405,877; 9/1/92 to 8/31/93
Provision of Pharmaceutical Care in Texas Prisons
11
From: Texas Department of Criminal Justice, Austin, TX
$1,479,781; 9/1/93 to 8/31/94
Co-Operative Research In New Drug Discovery & Delivery
From: M.D. Anderson Cancer Center
Houston, Tx
$65,000; 9/1/93 to 8/31/96
Provision of Pharmaceutical Care in Texas Prisons
From: UTMB Managed Care, Galveston, Tx.
$1,289,868; 9/1/94 to 8/31/95
Provision of Pharmaceutical Care in Texas Prisons
From: UTMB Managed Care, Galveston, Tx.
$1,465,380; 9/1/95 to 8/31/96
Sixth International Conference on Peripheral Dopamine
Camerino, Italy. June 28-July 1, 1996.
From: Roche Bioscience, Palo Alto, CA.
$1000
From: Merck & Co, Inc. West Point, PA
$3145
From: SmithKline Beecham, King of Prussia, PA
$1000
From: Zambon Group, Milan, Italy
$3500
From: University of Camerino, Camerino, Italy
$5000
From: Sandoz, Italy
$2000
Provision of Pharmaceutical Care in Texas Prisons
From: UTMB Managed Care, Galveston, Tx.
$1,682,652; 9/1/96 to 8/31/97
Provision of Pharmaceutical Care in Texas Prisons
From: UTMB Managed Care, Galveston, Tx.
$1,698,110; 9/1/97 to 8/31/98
Kidney Dopamine Receptor Function in Old Rats (AG 15031)
From: National Institute on Aging; National Institutes of Health
12
Bethesda, MD
$ 997,267; 7/1/98 to 12/31/03
Provision of Pharmaceutical Care in Texas Prisons
From: UTMB Managed Care, Galveston, Tx.
$1,752,481; 9/1/98 to 8/31/99
Provision of Pharmaceutical Care in Texas Prisons
From: UTMB Managed Care, Galveston, Tx.
$755,339; 9/1/99 to 3/12/00
Renal Dopamine Receptor Function in Obese Zucker Rats (DK 58743)
From: National Institute of Diabetes, Digestive and Kidney Diseases; NIH
Bethesda, MD
$ 895,000; 03/01/01 to 01/31/06
Kidney Dopamine Receptor Function in Old Rats (AG 15031-04S1)
From: National Institute on Aging; National Institutes of Health
Bethesda, MD
$ 79,176; 09/01/03 to 12/31/04
AFPE Pre-Doctoral Fellowship for Meghna Trivedi
From: American Foundation for Pharmaceutical Education
Rockville, MD
$6,000.00; 09/01/03 to 08/31/04
Age-Related Changes in Renal Dopamine Receptor Function (AG 25056)
From: National Institute on Aging; National Institutes of Health
Bethesda, MD
$ 1,485,000; 08/1/05 to 07/31/11
Renal Dopamine and Angiotensin II Receptor Function in Age-Related Hypertension
From: National Institute on Aging; National Institutes of Health
Betheda, MD
$ 1, 875,000; 09/01/11 to 08/31/16
Role: Co-Investigator
PI: Dr. Mahammad Asghar
13
COMMITTEE SERVICE
Department
Member, Graduate Education Committee, Department of Pharmacology, College of
Pharmacy, University of Houston (1978-1980).
Chairman, Graduate Education Committee, Department of Pharmacology, College of
Pharmacy, University of Houston (1980-1991).
College
Member, Admissions Committee, College of Pharmacy, University of Houston (1976-1978).
Member, Library Committee, College of Pharmacy, University of Houston, (1976-1990).
Member, Graduate Studies Committee, College of Pharmacy, University of Houston (19791981)
Member, Ad Hoc Curriculum Revision Committee, College of Pharmacy, University of
Houston (1979-1980).
Member, Executive Committee, College of Pharmacy, University of Houston (1980-1991).
Member, Accreditation Self-Study, College of Pharmacy, University of Houston (19851988).
Chair, Executive Council, College of Pharmacy, University of Houston (1991-2002).
Chair, Task Force on TMC Building Annex, College of Pharmacy, University of
Houston(2003-present)
University
Member, Research Council, University of Houston (1983-1986).
Chairman, Biomedical Research Support Grant Subcommittee, University of Houston (19831986).
Member, Internal Grants Program Subcommittee, University of Houston (1983-1984).
Member, Advisory Committee for International Affairs, University of Houston (1985-1986).
Member, Ad-Hoc Resarch Award Committee, University of Houston (1986-1987).
14
Member, Academic Council, University of Houston (1988-1991).
Member, Biomedical Research Support Grant Subcommittee, University of Houston (1989).
Member, Nominating Committee, Sigma Xi Scientific Research Society (1988-1991).
Member, Dean's Council (1991-2002)
Task Force on Faculty/Staff Merit Salary Increase (1994-95)
Task Force on HEAF Allocations (1994-95)
Task Force on Research Priorities (1995-96)
Task Force on Faculty Workload (1995-96)
Task Force on University Development (1995-96)
Task Force on Faculty Development (1996-97)
Task Force on Faculty Reward Systems (1996-97)
Member, Search Committee, Director of Animal Care Operations (2004-2005)
External
Member, Executive Committee, Texas Pharmacologists, 1980-1992.
Member, Texas Pharmacy Congress, 1991-2002
Member, Policy Council, Texas Medical Center, 1991-2002
Delegate, Council of Deans, American Association of Colleges of Pharmacy, 1991-2002
Member, Long Range Planning Committee, Texas Pharmaceutical Association, 1991-1993.
Member, President's Advisory Committee, Texas Society of Hospital Pharmacists, 19911993.
Member, Faculty Advisory Committee, Owen Healthcare, Inc. 1992-2000.
Member, Research Conflict of Interest Oversight Committee, UT Health Science CenterHouston 2003-present
CONTINUING EDUCATION SEMINARS
Mechanism of Action of Peripherally Acting Antihypertensive Agents. In: Continuing
Education Short Course on Hypertension and its Treatment,Wichita Falls, Texas, October,
1975.
Mechanism of Action and Therapeutic Uses of Some Newer Centrally Acting
Antihypertensive Agents. In: Continuing Education Short Course on New Concepts in
Drug Therapy, Houston, Texas, November 1976.
Morphine and Related Narcotics. In: Continuing Education Short Course on Drugs of
Abuse, Houston, Texas, March 1978.
15
Hypertension: Pathophysiology and Treatment In: Continuing Education Short Course on
Current Concepts in the Treatment of Cardiovascular Disease, Houston, Texas, March
1980.
Calcium Antagonists. In: Continuing Education Short Course on Clinical Pharmacology of
Selected Therapeutic Agents, Houston, Texas, November 1981.
Calcium Antagonists in the Treatment of Hypertension. In: Continuing Education Short
Course on Hypertension and Antihypertensive Agents, Houston, Texas, October 1984.
Etiology and Pathogenesis of Hypertension. In: Continuing Education Short Course on New
Concepts and New Drugs in Cardiovascular Diseases, Beaumont, Texas, November,
1985.
Angiotensin Converting Enzyme Inhibitors and Calcium Antagonists in Cardiovascular
Disease. In: Continuing Education Short Course on New Concepts and New Drugs in
Cardiovascular Diseases, Beuamont, Texas, November, 1985.
Pathophysiology of Hypertension. In: A Symposium on Hypertension in Blacks:
Pathophysiology and Treatment, Houston, Texas, October, 1986.
New Drug Discovery and Premarketing Evaluation of Drugs. May, 1995.
New Drugs for 1994. June, 1995.
SOCIETY MEMBERSHIPS
American Association for the Advancement of Science
American Society for Pharmacology and Experimental Therapeutics
Member, Committee on Public Affairs (1995-01)
Chair, Committee on Public Affairs (1996-01)
Member, Public Affairs Advisory Committee, FASEB (1996-99)
Member, Science Policy Committee, FASEB (1999-02)
Society for Experimental Biology and Medicine
International Society of Hypertension
Abstract Reviewer: Sixth Scientific Meeting, Heidelberg, Germany
Abstract Reviewer: Sixteenth Scientific Meeting, Glasgow, Scotland
Abstract Reviewer, Seventeenth Scientific Meeting, Amsterdam, The Netherlands
Fellow, Council for High Blood Pressure Research, American Heart Association
Council on Basic Science, American Heart Association
American Association of Colleges of Pharmacy
Member, Committee on Faculty Enterpreunership (1994-96)
Member, Finance Committee (1995-96)
Member, International Pharmaceutical Education Advisory Committee (2001-02)
Rho Chi
Fellow, American Society of Nephrology
Member, Program Committee, 2001 World Congress of Nephrology
Sigma Xi, The Scientific Research Society
Inter-American Society of Hypertension
Texas Pharmacy Association
Member, 1996 Pharmacist of the Year Selection Committee
Trustee, Texas Pharmacy Foundation (1996-97)
16
Texas Society of Health-Systems Pharmacists
The American Society of Hypertension
American Society of Health-Systems Pharmacists
Society for Free Radical Biology and Medicine,
Abstract Reviewer (2003, 2004, 2006)
The American Society for Cell Biology
ORGANIZATION OF MEETINGS AND SYMPOSIA
Member, Organizing Committee, Fall Meeting of the American Society for Pharmacology
and Experimental Therapeutics, Houston, TX 1978.
Chairman, Organizing Committee, Sixth Annual Meeting of Texas Pharmacologists,
Houston, TX 1980.
Member, Organizing Committee, Annual Meeting of Scientists of Indian Origin, Society for
Neuroscience, Dallas, TX 1983.
Co-Organizer, Symposium on Dopaminergic Systems in Hypertension, Gent, Belgium 1986.
Co-Organizer, Scientific Program, Thirteenth Annual Meeting of Texas Pharmacologists,
Galveston, TX 1989.
Co-Organizer, Annual Meeting of the S.W. Section of the Society for Expermental Biology
& Medicine, Houston, TX 1989.
Co-Organizer, Symposium on Significance of Peripheral Dopaminergic System in
Cardiovascular and Renal Function, Essen, West Germany 1990.
Co-Organizer, Symposium on New Cardiovascular Drugs, Acapulco, Mexico 1991.
Member, Advisory Committee, 5th International Conference on Peripheral Dopamine,
Kyoto, Japan, 1994.
Member, Scientific Committee, Interaction in the Practice of Internal Medicine and
Endocrinology, Capri, Italy, 1994.
Co-organizer, 6th International Conference on Peripheral Dopamine, Camerino, Italy, 1996.
Member, Planning Committee, USP South Regional Meeting, Houston, Tx., 1997.
Chairman, International Scientific Advisory Committee, Symposium on Emerging Trends in
Diabetes and Hypertension, Ahmedabad, India, 1997.
Co-organizer, Symposium on The Role of Renal Dopamine Receptors in Hypertension at the
EB’99 Meeting in Washington, D.C. April, 1999.
Member, Scientific Program Committee, 8th International Conference on Peripheral
Dopamine, Stockholm, Sweden, June, 2002.
Member, International Scientific Committee, Pan Arab Congress of Pharmacology, Fez,
Morocco, September, 2002.
17
Member, International Advisory Board, 9th National Conference on Bioactive Heterocycles
and Drug Discovery Paradigm, Rajkot, India, January, 2005.
INVITATIONS TO NATIONAL & INTERNATIONAL MEETINGS
International Symposium on Central Actions of Angiotensin and Related Hormones,
Houston, TX, January 1976.
International Symposium on Hypertension and Antihypertensive Agents, Texas Medical
Center, Houston, TX, October 1977.
Symposium on Dopamine Receptor Mechanisms, The New York Academy of Sciences,
New York, NY, May 1979.
International Symposium on Central Nervous System Mechanisms in Hypertension,
Houston, TX, May 1980.
Symposium on Receptor Mechanisms in Pharmacology, Puerto Vallarta, Mexico, January
1983.
First Smith Kline & French Laboratories Annual Research Symposium on Dopamine
Receptor Agonists, Philadelphia, PA. February 1983.
Symposium on Calcium Channel Blockers, Asian Congress of Pharmacology, New Delhi,
India, January 1985.
International Symposium on Chemical Modulation of Neural Function, Calcutta, India,
January 1985.
Symposium on The Role of Peripheral Dopamine Receptors in Cardiovascular Function,
FASEB Meeting, Anaheim, CA, April 1985.
Symposium on Brain Peptides and Catecholamines in Cardiovascular Regulation in
Normal and Disease States, Houston, TX., January, 1986.
Symposium on CNS Actions of Dopamine, Texas Pharmacologists Meeting, Galveston, TX.,
May, 1986.
Symposium on Dopaminergic Systems in Hypertension, Gent, Belgium, September, 1986.
Fifth Capo Boi Conference on Neuroscience, Symposium on Similarities and
Dissimilarities Between Central and Peripheral Dopamine Receptors, Villasimius,
Sardinia, Italy, May, 1987.
Symposium on Peripheral Actions of Dopamine, Melbourne, Australia, August, 1987.
Department Chairmen's Symposium, Texas Pharmacologists, Austin, TX., June, 1988.
18
Symposium on Receptors and Signal Transduction, Southwestern Section of Society for
Experimental Biology and Medicine, Dallas, TX., November, 1988.
Symposium on Dopamine Receptors and Pharmacotherapy of Heart Failure, RottachEagern, West Germany, July, 1989.
Seventh Meeting on Adrenergic Mechanisms, Porto, Portugal, October, 1989.
3rd International Symposium on Peripheral Actions of Dopamine, Charlottesville, VA.,
October, 1989.
Symposium on Ibopamine: New Pharmacotherapeutic Approach to Heart Failure, Kyoto,
Japan, October, 1989.
Dopaminergic Agents in Vital Organ Perfusion, Amsterdam, The Netherlands, June, 1990.
Dopacard Workshop: Toward Improving Vital Organ Perfusion, Stockholm, Sweden,
June, 1990.
Satellite Symposium on Significance of Peripheral Dopaminergic System in
Cardiovascular and Renal Function, Essen, West Germany, July, 1990.
11th International Symposium on Intensive Care and Emergency Medicine, Brussels,
Belgium, March, 1991.
Symposium on Renal Actions of Dopexamine Hydrochloride, Brussels, Belgium,
March, 1991.
Symposium on Improving Vital Organ Function - The Role of Dopexamine
Hydrochloride, Montreux, Switzerland, September, 1991.
Symposium on Regional Blood Flow, London, England, November, 1991.
ISH - Workshop on Hypertension and Receptors, Amsterdam, The Netherlands, November,
1991.
XXIVth Annual Meeting of Indian Pharmacological Society, Ahmedabad, India,
December, 1991.
5th Annual Meting of the Indo-American Pharmaceutical Society, New York, N.Y. April,
1992.
4th International Conference on Peripheral Dopamine, Porto, Portugal, June, 1992.
7th International Catecholamine Symposium, Amsterdam, The Netherlands, June, 1992.
113th Annual Meetimg of the Texas Pharmaceutical Association, Houston, Tx. June, 1992.
7th Annual Region D Meeting of the Texas Pharmaceutical Association, San Antonio, Tx.
April, 1993.
Interactions in the Practice of Internal Medicine and Endocrinology, Capri, Italy,
September, 1994.
19
5th International Coference on Peripheral Dopamine, Kyoto, Japan, October, 1994.
Renal Dopaminergic Mechanisms in Hypertension, Sapporo, Japan, October, 1994.
American Association of Colleges of Pharmacy : Isuues of State Funding for Education
and Research, Washington,D.C. March, 1995.
15th Internatinal Symposium on Intensive Care and Emergency Medicine, Brussels,
Belgium, March, 1995.
Texas Society of Health-Systems Pharmacists: Panel Discussant, Corpus Christi, Texas,
April, 1996.
6th International Conference on Peripheral Dopamine, Camerino, Italy, July, 1996.
9th Meeting on Adrenergic Mechanisms, Porto, Portugal, September, 1996.
Drug Policy Forum of Texas, Houston, Tx., October, 1996.
Eckerd Conference on the Future of Managing Pharmaceutical Care, Clearwater, Florida,
November, 1996.
FASEB Consensus Conference on Federal Funding, Washington, D.C., November, 1996.
Texas Society of Health-Systems Pharmacists: Panel Discussant, Austin, Texas, April,
1997.
Eckerd 2nd Annual Healthcare Summit, St.Petersburg, Florida, November, 1997
First Asia-Pacific Congress on Hypertension, Surat, India, November, 1997.
Symposium on Emerging Trends in Diabetes and Hypertension, Ahmedabad, India,
December, 1997.
7th International Conference on Peripheral Dopamine, Dublin, Ireland, August, 1998.
34th Scientific Meeting of the Society for the Spontaneously Hypertensive Rat, Kyoto,
Japan, October, 1998.
Experimental Biology ‘99 Symposium on The Role of Renal Dopamine Receptors in
Hypertension, Washington, D.C. April, 1999.
Acta Physiologica Scandanavica Symposium on Vasodilators in the Development of
Hypertension: NO and Dopamine, Uppsala, Sweden, June, 1999.
Symposium on Dopamine and Blood Pressure Regulation, 2nd European Congress of
Pharmacology, Budapest, Hungary, July, 1999.
1st International Congress of Hypertension: From Pathophysiology to
Treatment, Fez, Morocco, October, 1999.
American Association of Colleges of Pharmacy Annual Meeting:Forum on
Pharm.D./Ph.D. Programs, San Diego, CA, July, 2000.
20
4th Annual Houston International Community Health Summit, Houston, Tx.
September, 2000.
27th Annual Texas Federation of Drug Store Convention, Austin, Tx. October, 2001.
Education Connection Conference, Rite Aid Corporation, Philadelphia, PA.,
November, 2001.
American Association of Colleges of Pharmacy Interim Meeting, Houston, Tx.
March, 2002.
Partnership in Pharmacy Focus 2002 Conference, Palm Harbor, FL. April, 2002.
8th International Conference on Peripheral Dopamine, Stockholm, Sweden, June,
2002.
Fourth Annual John H. Laragh Conference on Advances in Hypertension Research,
The American Society of Hypertension, Coral Gables, FL. January, 2003.
Biology of the Aging Kidney Workshop, National Institute on Aging, Bethesda, MD,
January, 2003.
Seventh Annual Diabetes Conference, The SMi Group, London, England, October,
2005
The Biology of Aging, Gordon Research Conference, Ventura, CA, February, 2006.
The 12th International SHR Symposium, Kyoto, Japan, October, 2006
The 13th Innternational SHR Symposium, Prague, the Czec Republic, June, 2008
Symposium on R alpha lipoic acid, Rome, Italy, September, 2010.
INVITATIONS FOR SEMINARS
Division of Gynecology, Memorial Hospital, Houston, TX, April 1977.
Department of Neurology, New York University Medical Center, New York, NY, May 1979.
Department of Pharmacology, New Jersey College of Medicine and Dentistry, Newark, NJ,
May 1979.
Department of Pharmacology, University of Kentucky, College of Medicine, Lexington, KY,
June 1979.
Department of Pharmacology, Smith Kline Corporation, Philadelphia, PA, January 1981.
21
Department of Biology, Synthelabo, L.E.R.S., Paris, France, June 1981.
Department of Pharmacology, Texas College of Osteopathic Medicine, Ft. Worth, TX, June
1982.
Department of Pharmacology, Smith Kline Corp., Philadelphia, PA, June 1982.
Department of Cardiovascular Pharmacology. Eli Lilly & Co., Indianapolis, IN, November
1982.
Department of Pharmacology, Syntex Research, Palo Alto, CA, June 1983.
Department of Biology, Texas Southern University, Houston, TX, February 1984.
Division of Cardiology, St. Luke's Episcopal Hospital & Texas Heart Institute, Houston, TX,
March 1984.
Department of Pharmacology, L.M. College of Pharmacy, Ahmedabad, India, January 1985.
Department of Pharmacology, College of Medicine & Dentistry, Newark, NJ, March 1985.
Department of Cardiovascular Pharmacology, Ayerst Research Laboratories, Princeton, NJ,
August 1985.
Department of Cardiovascular Research, Rhone-Poulenc Sante, Paris, France, September,
1986.
Department of Physiology, University of Goteborg, Goteborg, Sweden, September, 1986.
Houston Pharmacological Center, UT Medical School, Houston, TX, April, 1987.
Department of Biology, Prairie View A&M University, Prairie View, TX, September, 1987.
Department of Pharmacology, Schering Corporation, Bloomfield, NJ, November, 1987.
Department of Neuroscience, University of Rome, Rome, Italy, December, 1987.
Division of Endocrinology, University of Florence, Florence, Italy, December, 1987.
Liposome Technology, Inc., Menlo Park, CA, February, 1988.
Department of Pharmacology, Squibb Institute for Medical Research, Princeton, NJ, March,
1988.
Department of Pharmacology, Berlex Laboratories, Cedar Knoll, NJ, March, 1989.
Department of Pharmacology, Smith Kline & French Laboratories, Swedeland, PA, June,
1989.
Cardiovascular Research Group, Simes Laboratories, Zambon Corporation, Milan, Italy,
July, 1989.
Institute of Pharmacology, Erasmus University, Rotterdam, The Netherlands, June, 1990.
22
Department of Internal Medicine, University of Texas Medical School at Houston, Houston,
TX, May, 1991.
Division of Nephrology, University of Texas Medical Branch at Galveston, Galveston, TX,
June, 1991.
Department of Cardiovascular and Respiratory Science, University of Rome-La Sapienza,
Rome, Italy, October, 1991.
Department of Intensive Care, Erasme University Hospital, Brussels, Belgium, December,
1991.
Indian Medical Association, Palanpur, India, December, 1991.
Department of Pharmacology, University of Texas Medical Branch at Galveston, Galveston,
TX, April, 1992.
Division of Nephrology, University of Texas Medical Branch at Galveston, Galveston, TX.
October, 1993.
Sigma Xi, The Scientific Research Society, University of Houston Chapter, Houston, TX.
November, 1993.
Faculty of Pharmacy, University of Camerino, Camerino, Italy. June, 1994.
The Speywood Laboratories, Ltd. London, England. June, 1994.
Department of Physiology, Trinity Collge Dublin, Dublin, Ireland. September, 1996.
Indian Medical Association, Palanpur, India. December, 1997.
Department of Pharmacology, University of California-San Diego, La Jolla, CA. August,
1998.
Department of Pharmacology, Kinki University School of Medicine, Osaka, Japan,
September, 1998.
Graduate School of Medicine, Kinki University, Osaka, Japan, September, 1998.
Department of Pharmacology, Mt. Sinai University School of Medicine, New York, NY,
December, 1998.
Department of Pharmacology, Molecular Pharmacology and Renal Physiology Unit,
INSERM, Toulouse, France, June, 2001.
Dyslipedimia Research Laboratories, Astra-Zeneca, Molndal, Sweden, June, 2002.
Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy,
University of Houston, Houston, Tx. January, 2003.
Department of Biology and Biochemistry, College of Natural Sciences and Mathematics,
University of Houston, Houston, Tx. February, 2003.
Faculty of Pharmacy, University of Camerino, Camerino, Italy, October, 2004.
23
Washington County Rotary Club, Brenham, Tx. March, 2005.
Department of Health and Kinesiology, Texas A&M University, College Station, Tx.
November, 2006.
School of Pharmacy, Texas Tech University Health Sciences Center Amarillo, Tx.
January, 2007
Department of Pharmacology, The Third Military Medical University, Chogqing, P.R.China,
March, 2007
Deprtmant of Cardiology, The Third Military Medical University, Chogqing, P.R.China,
March, 2007
Department of Pharmacology and Neuroscience, University of North Texas Health Sciences
Center, Forth Worth, TX. March, 2008
Deaprtmant of Pharmacology, University of Medicine and Dentistry of New Jersey, Newark,
NJ. April, 2008.
Faculty of Pharmacy, University of Camerino, Camerino, Italy, October, 2008.
EXTERNAL GRANTS & OTHER REVIEWS
Member:
Site Visit Committee, National Institute of General Medical Sciences, NIH,
1980, 1981.
Site Visit Committee, National Center for Research Resources, NIH, 1992.
Member:
Special Review Committee, Pharmacological Sciences , NIGMS, March, 1987.
Special Review Group, Experimental Cardiovascular Science, NHLBI,
October, 1992.
Member:
Scientific Advisory Committee, RCMI Program Project, Texas Southern
University, 1995-2000
Proposal Reviewer: National Science Foundation, 1980, 1984, 1985, 1992, 2000.
The National Kidney Foundation, 1997
Reviewer: Ph.D. Programs in Pharmacology, National Research Council, 1993.
Reviewer: Developmental Research Projects, RCMI Program for Texas Southern University
1993.
Evaluation Team Member: American Council on Pharmaceutical Education, 1994.
Reviewer: Italian Ministry for Education University and Research, 2001-present
Member: Cardiovascular and Renal Study Section, CSR/NIH
July 1, 2002 – October 31, 2003.
Cellular and Molecular Biology of the Kidney Study Section, CSR/NIH
24
March 1, 2004- June 30, 2006.
Member: CSR/NIH, Special Emphasis Review Panel, November, 2006.
Ad-hoc Member: Hypertension Microcirculation Study Section, October, 2008, January,
2009, September, 2009, June, 2010.
Member:
NHLBI Spring Hypertension Program Project Review Group, May, 2003
NHLBI Special Emphasis Panel Program Project Review Group, May, 2006
NHLBI Special Emphasis Panel Program Project Review Group, October, 2008
Member:
Review Panel, Oklahoma Center for the Advacement of Science and
Technology, April, 2007.
EDITOR-IN-CHIEF
Clinical and Experimental Hypertension (1993- present)
ASSOCIATE EDITOR
Clinical & Experimental Hypertension (1992-1993)
EDITORIAL BOARDS
Clinical & Experimental Hypertension (1985-1991)
Drug Development Research (1986-1992)
Journal of Cardiovascular Pharmacology (1987-1998)
Hypertension Research (1999-present)
Experimental Biology & Medicine (2000-2005)
Journal of Epithelial Biology and Pharmacology (2008-present)
MANUSCRIPT REVIEWS (1975-present)
Life Sciences
European Journal of Pharmacology
Journal of Pharmacology & Experimental Therapeutics
Journal of Autonomic Pharmacology
Circulation Research
American Journal of Physiology : Heart & Circulatory Physiology
American Journal of Physiology: Renal, Fluid & Electrolyte Physiology
American Journal of Physiology: Regulatory , Imtegrative & Comparative Physiology
American Journal of Physiology: Endocrinology & Metabolism
American Journal of Physiology: Cell Physiology
Pediatric Nephrology
Hypertension
Federation Proceedings
Pharmacological Reviews
Brain Research Bulletin
Journal of Clinical Investigation
Research Communications in Chemical Pathology & Pharmacology
25
Journal of Pharmaceutical Sciences
Archives Internationales de Pharmacodynamie et de Therapie
Naunyn-Schmiedeberg's Archives of Pharmacology
Circulation
Circulation Research
Biochemical Pharmacology
Fundamental & Clininical Pharmacology
Clinical Intensive Care
The International Journal of Biochemistry & Cell Biology
Molecular Pharmacology
Pharmacology and Therapeutics
American Journal of Hypertension
Kidney International
Journal of Neurochemistry
Experimental Biology & Medicine
Journal of Hypertension
Cellular and Molecular Biology
American Journal of Kidney Diseases
Science
Physiological Genomics
Proceedings of the National Academy of Sciences
Acta Physiologica Scandavavica
British Journal of Pharmacology
Neuroscience Letters
Nephron
Current Medicinal Chemistry-Cardiovascular and Hematological Agents
Non-Linearity in Biology, Toxicology and Medicine
Nature Clinical Practice Nephrology
American Journal of Nephrology
Journal of Aging Research
26
PUBLICATIONS
Books & Journals
1.
Central Actions of Angiotensin and Related Hormones, Eds. J. P. Buckley and C.M.
Ferrario. Assoc. Ed. M.F. Lokhandwala, Pergamon Press, Inc., New York, 1977.
2.
Central Nervous System Mechanisms in Hypertension, Eds. J. P. Buckley and C.M.
Ferrario, Assoc. Ed. M.F. Lokhandwala, Raven Press, New York, 1981.
3.
Brain Peptides and Catecholamines in Cardiovascular Regulation, Eds. J. P.
Buckley and C. M. Ferrario. Assoc. Ed. M. F. Lokhandwala, Raven Press, New York
1987.
4.
Proceedings of a Symposium on Dopaminergic Systems in Hypertension, Eds. M. F.
Lokhandwala, M. G. Bogaert and R. A. Lefebvre. Clinical & Experimental
Hypertension, A9: 5 & 6, 1987.
5.
Proceedings of Symposium on Significance of Peripheral Dopaminergic System in
Cardiovascular and Renal Function, Eds. M. F. Lokhandwala, F. Amenta and O.-E.
Brodde. Journal of Autonomic Pharmacology, 10 (Suppl 1): 1990.
6.
Science of Drug Action: Course Outline, Eds. T. L. Lemke and M. F. Lokhandwala,
Kendall/Hunt Publishing Co., Dubuque, Iowa, 1990.
7.
Principles of Drug Action: Course Outline, Eds. K. Alkadhi, F. Bove, T. Lemke and
M. F. Lokhandwala, University of Houston, Houston,Tx. 1995.
8.
Proceedings of the 6th International Conference on Peripheral Dopamine, Eds. F.
Amenta and M. F. Lokhandwala. Clinical & Experimental Hypertension, 19: 1&2,
1997.
9.
Proceedings of the International Symposium on Emerging Trends in Diabetes
Mellitus and Hypertension, Eds. R.K. Goyal and M.F. Lokhandwala. Clinical &
Experimental Hypertension, 21: 1&2, 1999.
10.
R(+) Dalla Ricerca Di Base Alle Applicazioni Cliniche Dell’enantiomero Naturale
Di Un Antiossidante Multifunzione, Eds. A. Amenta, V. Costigliola and M.F.
Lokhandwala. Pacine Editore S.p.A., Pisa, Italy, 2010.
Book Chapters
1.
Lokhandwala, M.F. and Buckley, J.P.: Studies on the interactions of clonidine with
the hypertensive activity of angiotensin II, In: Central Actions of Angiotensin and
Related Hormones, Eds. J.P. Buckley and C.M. Ferrario, Pergamon Press, New York,
215-224, 1977.
27
2.
Buckley, J.P., Vollmer, R.R. and Lokhandwala, M.F. and Jandhyala, B.S.: Drug
actions on cardiovascular dynamics, In: Cardiovascular Flow Dynamics and
Measurements, Eds. N.G.C. Hwang and N.A. Norman, University Park Press,
Baltimore, 73l-756, 1977.
3.
Buckley, J.P., Saelens, D., Lokhandwala, M.F. and Jandhyala, B.S.: Central actions
of angiotensin II in dogs, In: Essential Hypertension, Ed. R.H. Thurm, Year Book
Medical Publishers, Chicago, 299-315, 1979.
4.
Buckley, J.P., Lokhandwala, M.F., Jandhyala, B.S., Francis, J.S. and Tadepalli, A.S.:
Circulatory effects of chronic intraventricular administration of angiotensin II in dogs,
In: Central Nervous System Mechanisms in Hypertension, Eds. J.P. Buckley and C.M.
Ferrario, Raven Press, New York, 363-375, 1981.
5.
Eikenburg, D.C., Ekas, R.D. and Lokhandwala, M.F., Presynaptic modulation of
norepinephrine release by a-adrenoceptors and angiotensin II receptors in
spontaneously hypertensive rats, In: Central Nervous System Mechanisms in
Hypertension, Eds. J.P. Buckley and C.M. Ferrario, Raven Press, New York, 215-228,
1981.
6.
Lokhandwala, M.F. and Barrett, R.J.: Pharmacological role of presynaptic dopamine
receptors in the Cardiovascular Actions of Dopaminergic Agents, In: Central Nervous
System Mechanisms in Hypertension, Eds. J.P. Buckley and C.M. Ferrario, Raven
Press, New York, 203-213, 1981.
7.
Jandhyala, B.S., Saelens, D., Lokhandwala, M.F. and Buckley, J.P.: Cardio-vascular
effects of chronic administration of angiotensin II into cerebrolateral ventricles of dogs,
In: Hypertension, Ed. H. Villarreal, John Wiley and Sons, Inc. New York, 209-218,
1981.
8.
Buckley, J.P., Jandhyala, B.S. and Lokhandwala, M.F.: Effects of central angiotensin
on renin release from the kidney, In: The Renin Angiotensin System in the Brain, Eds.
D. Ganten, M.P. Printz and M.I. Phillips, Springer-Verlag, New York, 365-372, 1982.
9.
Lokhandwala, M.F. and Barrett, R.J.: Dopamine receptor agonists and hypertension,
In: Dopamine Receptor Agonists, Eds. G. Poste and S.J. Crooke, Plenum, New York,
209-223, 1984.
10.
Eikenburg, D. C., Peter, E. J. and Lokhandwala, M. F.: Effects of calcium channel
blockers on pre- and post-junctional noradrenregic mechanisms in the isolated perfused
rat kidney. In: Proceedings of the Asian Congress of Pharmacology, Ed. B. N.
Dhawan, Allied Publishers, New Delhi, India, 1986.
11.
Lokhandwala, M. F.: Dopamine receptor agonists and cardiovascular neuroeffector
function, In: Brain Peptides and Catecholamines in Cardiovascular Regulation, Eds. J.
P. Buckley and C. M. Ferrario, Raven Press, New York, NY, 65-77, 1987.
12.
Lokhandwala, M. F., DeFeo, M. L. and Cavero, I: Physiological and pharmacological
significance of dopamine receptors in the cardiovascular system, In: Progress in
Hypertension (Vol. I); Neurotransmitters as Modulators of Blood Pressure, Ed. H.
Saito, VSP, Zeist, The Netherlands, 115-144, 1988.
28
13.
Lokhandwala, M. F.: Identification of two distinct subtypes of dopamine receptors in
sympathetic ganglia, In: Symposia in Neuroscience, Eds. G. Biggio, P. F. Spano, G.
Toffano and G. L. Gessa, Liviana Press-Springer Verlag, 15-21, 1988.
14.
Lokhandwala, M. F. and DeFeo, M. L.: Neuronal dopamine receptors, In: Peripheral
Actions of Dopamine, Ed. C. Bell and B. McGrath, McMillan, 153-171, 1988.
15.
Lokhandwala, M. F. and Hegde, S. S.: Cardiovascular pharmacology of dopamine
receptor agonists, In: Peripheral Dopamine Pathophysiology, Ed. F. Amenta, CRC
Press Inc., Boca Raton, Florida, 63-77, 1990.
16.
Lokhandwala, M.F.: Role of kidney dopamine in sodium excretion, In: Peripheral
Dopamine Pathophysiology, Ed. F. Amenta, CRC Press Inc., Boca Raton, Florida, 7985, 1990.
17.
Lokhandwala, M. F., Sabouni, M. H. and Alkadhi, K. A.: Cardiac and vascular
consequences of modulation and sympathetic neurotransmission by dopaminergic
agonists, In: The Cardiovascular Function of Peripheral Dopamine Receptors, Ed. J.
P. Hieble, Marcel Dekker, New York, NY, 133-149, 1990.
18.
Lokhandwala, M. F.: Effects of dopamine receptor agonists on cardiovascular and
renal function, In: Updates in Intensive Care and Emergency Medicine, Ed. J. L.
Vincent, Springer-Verlag, 74-80, 1991.
19.
Chen, C. J., Vyas, S. J., Eichberg, J., Beach, R. E. and Lokhandwala, M. F.:
Abolished DA-1 receptor mediated inhibition of renal tubular Na+,K+-ATPase in
spontaneously hypertensive rats, In: Genetic Hypertension, Ed. J. Sassard, John
Libbey Eurotext, 463-465, 1992.
20.
Chen C. J. and Lokhandwala, M. F.: Impairment of renal dopamine receptor function
in spontaneously hypertensive rats. In: Advances in the Biosciences Volume 88 ;
Cardiovascular and Renal Actions of Dopamine. Ed. P. Soares-da-Silva , Pergamon
Press, Oxford, 143-154, 1993.
21.
Lokhandwala, M. F.: Role of kidney dopamine and dopamine receptors in the
regulation of sodium excretion. In: Experimental Cardiology, Ed.C. Casagrande, CnM
Edizione Scientifiche, Coromano, Italy, 119-133, 1993.
22.
Lokhandwala, M.F. and Chen, C.J.: Peripheral dopamine receptors, In: Peripheral
Dopamine Receptor Function and Pharmacology, Ed. H.B. Niznik, Marcell Dekker,
Inc. New York, 89-92,1994.
23.
Lokhandwala, M.F., Jandhyala,B.S. and Jacinto S.M.: Dopaminergic drugs in
cardiovascular emergencies, In: Yearbook of Intensive Care and Emergency Medicine,
Ed. J.L.Vincent, Springer-Verlag, 945-954, 1995.
24.
Lokhandwala, M.F.: Acido tioctio: farmacologia ed applicazioni terapeutiche di un
antiossidante particolare. In: R(+) Dalla Ricerca Di Base Alle Applicazioni Cliniche
Dell’enantiomero Naturale Di Un Antiossidante Multifunzione, Eds. A. Amenta, V.
Costigliola and M.F. Lokhandwala. Pacine Editore S.p.A., Pisa, Italy, 2010.
29
Review Articles
1.
Lokhandwala, M.F.: Presynaptic receptor systems on cardiac sympathetic nerves. Life
Sci. 24:l823-l832, l979.
2.
Lokhandwala, M.F. and Barrett, R.J.: Cardiovascular dopamine receptors:
Physiological Pharmacological and Therapeutic implications, J. Autonomic Pharmacol.
3:l89-215, l982.
3.
Lokhandwala, M.F. and Eikenburg, D.C.: Presynaptic receptors and alterations in
norepinephrine release in spontaneously hypertensive rats, Life Sci. 33:1527-1542,
1983.
4.
Lokhandwala, M.F. and Barrett, R.J.: Dopamine receptor agonists in cardiovascular
therapy, Drug Develop. Res. 3:299-310, l983.
5.
Eikenburg, D. C. and Lokhandwala, M. F.: Calcium antagonists and sympathetic
neuroeffector function, J. Autonomic Pharmacol. 6: 237-255, 1986.
6.
Lokhandwala, M. F.: Preclinical and clinical studies on the cardiovascular effects of
fenoldopam, a DA-1 receptor agonists, Drug Develop. Res., 10:123-134, 1987.
7.
Lokhandwala, M. F.: Cardiovascular and renal effects of dopamine receptor agonists,
ISI Atlas of Science: Pharmacology, 2:261-266, 1988.
8.
Lokhandwala, M .F. and Hegde, S. S.: Cardiovascular dopamine receptors: Role of
renal dopamine and dopamine receptors in sodium excretion, Pharmacology &
Toxicology, 66: 237-243, 1990.
9.
Hegde, S. S. and Lokhandwala, M.F.: Renal dopamine and sodium excretion, Amer.
J. Hyperten. 3:78S-81S. 1990.
10.
Lokhandwala, M. F. Renal actions of dopexamine hydrochloride, Clin. Int. Care,
1:163-174, 1990.
11.
Lokhandwala, M. F., Vyas, S. J. and Hegde, S. S.: Renal dopamine and tubular DA-1
receptors in the regulation of sodium excretion. J. Auton. Pharmacol. 19(Suppl
1):S31-S39, 1990.
12.
Chintala, M. S., Lokhandwala, M. F. and Jandhyala, B. S.: Protective effects of
dopexamine hydrochloride in renal failure after acute hemorrhage in dogs. J. Auton.
Pharmacol. 10(Suppl 1):S95-S102, 1990.
13.
Lokhandwala, M. F. and Hegde, S. S.: Cardiovascular pharmacology of adrenergic
and dopaminergic receptors: Therapeutic significance in congestive heart failure, Am.
J. Med. 90(Suppl. 5B): 2S-9S, 1991.
14.
Lokhandwala, M. F., Amenta, F. and Jandhyala, B. S.: Renal research on dopexamine
hydrochloride, Clin. Int. Care, 2:12-15, 1991.
15.
Lokhandwala, M. F. and Amenta, F.: Anatomical distribution and function of
dopamine receptors in the kidney. FASEB Journal, 5:3023-3030, 1991.
30
16.
Lokhandwala, M. F. and Jandhyala, B. S.: Effects of dopaminergic agonists on organ
blood flow and function, Clin. Int. Care, 3:12-15, 1992.
17.
Chen, C. J. and Lokhandwala, M. F.: Dopaminergic receptors in hypertension,
Pharmacology & Toxicology, 70: s11-s16, 1992.
18.
Chen, C. J. and Lokhandwala, M. F.: Dopamine receptor agonists in cardiovascular
pharmacotherpy, Indian J. Pharmacology, 24: 72-81, 1992.
19.
Lokhandwala,M.F., Kansra, V. and Chen,C.J.: Dopaminergic modulation of Na,KATPase activity in the proximal tubules of normotensive and hypertensive rats.
Hypertension Res. 18 Suppl.I: S43-S46, 1995.
20.
Hussain, T. and Lokhandwala, M. F.: Dopamine-1 receptor G-protein coupling and
the involvement of phospholipase A2 in the dopamine-1 receptor-mediated cellular
signaling mechanisms in the proximal tubules of SHR. Clin. Exp. Hyperten. 19: 131140, 1997.
21.
Jacinto,S. M., Chintala, M. S., Lokhandwala, M. F. and Jandhyala, B. S.: Efficacy and
mechanisms of dopexamine in the prevention of ischemia-reperfusion induced organ
damage: role of oxygen free radicals. Clin. Exp. Hyperten. 19: 181-190, 1997.
22.
Hussain,T. and Lokhandwala, M. F.: Renal dopamine receptor function in
hypertension. Hypertension, 32: 187-197, 1998.
23.
Hussain, T., Kansra, V. and Lokhandwala, M.F.: Renal dopamine receptor signaling
mechanisms in spontaneously hypertensive and Fisher 344 old rats. Clin. Exp.
Hyperten. 21: 25-36, 1999.
24.
Hussain, T. and Lokhandwala, M.F.: Renal dopamine receptors and hypertension.
Exp.Biol.Med. 228: 134-142, 2003.
25.
Banday, A. A. and Lokhandwala, M. F.: Dopamine receptors and hypertension. Curr.
Hypertension Reports 10: 268-275, 2008.
26.
Tayebati, S. K., Lokhandwala, M.F. and Amenta, F: Dopamine and vascular
dynamics control: Present Status and futurte perspectives. Current Neurovascular
Research, in press, 2011.
27.
Asghar, M., Tayebati, S.K., Lokhandwala, M.F and Hussain, T.: Potential
Dopamine-1 Receptor Stimulation in Hypertension Management. Curr.
Hypertension Reports, in press, 2011.
Research Papers
1.
Lokhandwala, M.F., Patel, D.B., Patel, H., Merker, P.C., Shafiee, A. and Hite, G.:
Stereochemical investigations of local anesthetic action, J. Pharm. Sci. 60: 685-689,
1971.
31
2.
Lokhandwala, M.F., Cavero, I., Buckley, J.P. and Jandhyala, B,S.: Influence of
pentobarbital anesthesia on the effects of certain autonomic blocking agents on heart
rate, Europ. J. Pharmacol. 24: 274-277, 1973.
3.
Cavero, I., Lokhandwala, M.F., Buckley, J.P. and Jandhyala, B.S.: The effect of (-)delta 9-trans-tetrahydrocannabinol on myocardial contractility and venous return in
anesthetized dogs, Europ. J. Pharmacol. 29: 74-82, 1974.
4.
Lokhandwala, M.F., Buckley, J.P. and Jandhyala, B.S.: Effect of methyldopa
treatment on peripheral sympathetic nerve function in the dog, Europ. J. Pharmacol.
32: 170-178, 1975.
5.
Lokhandwala, M.F., Buckley, J.P. and Jandhyala,: B.S.: Effect of methyldopa
treatment on cardiac function and myocardial blood flow in mongrel dogs, Proc. Soc.
Exp. Biol. Med. 151: 466-470, 1976.
6.
Lokhandwala, M.F., Buckley, J.P. and Jandhyala, B.S.: Studies on the mechanism of
cardiovascular effects of methyldopa, Europ. J. Pharmacol. 37: 79-89, 1976.
7.
Lokhandwala, M.F., Asaad, M.M. and Buckley, J.P.: Effect of propranolol on vascular
responses to sympathetic nerve stimulation and plasma renin activity in mongrel dogs,
Europ. J. Pharmacol., 38: 141-147, 1976.
8.
Lokhandwala, M.F. and Buckley, J.P.: Effect of presynaptic alpha-adrenoceptor
blockade on responses to cardiac nerve stimulation in anesthetized dogs, Europ. J.
Pharmacol. 40: 183-186, 1976.
9.
Lokhandwala, M.F. and Buckley, J.P.: Analysis of presynaptic inhibitory actions of
various dopamine analogs on sympathetic neurotransmission in mongrel dogs, Life Sci.
20: 507-516, 1977.
10.
Lokhandwala, M.F., Coates, J.T. and Buckley, J.P.: Effects of several catecholamines
on sympathetic transmission to the myocardium: Role of presynaptic alphaadrenoceptors, Europ. J. Pharmacol. 42: 257-265, 1977.
11.
Lokhandwala, M.F., Pariani, H.K., Buckley, J.P. and Jandhyala, B.S.: Involvement of
central alpha-adrenoceptors in the hypotensive and bradycardiac effects of (-)-∆9transtetra- hydrocannabinol, Europ. J.Pharmacol. 42: 107-112, 1977.
12.
Lokhandwala, M.F., Buckley, J.P. and Jandhyala, B.S.: Effect of methyldopa
treatment on vagal cardioaccelerator system, Ind. J. Pharmacol. 9: 247-251, 1977.
13.
Lokhandwala, M.F. and Buckley, J.P.: Presynaptic dopamine receptors as mediators
on dopamine-induced inhibition of neurogenic vasoconstriction, Europ. J. Pharmacol.
45: 305-309, 1977.
14.
Lokhandwala, M.F. and Buckley, J.P.: The effect of L-dopa on peripheral sympathetic
nerve function: Role of presynaptic dopamine receptors. J. Pharmacol. Exp. Therap.
204: 362-371, 1978.
15.
Lokhandwala, M.F., Buckley, J.P. and Jandhyala, B.S.: Reduction of plasma renin
activity by centrally-administered angiotensin II in anesthetized cats, Clin. Exp.
Hypertension, 1: 167-175, 1978.
32
16.
Lokhandwala, M.F.: Inhibition of sympathetic nervous system by histamine:
Studieswith H1-and H2-receptor antagonists, J. Pharmacol. Exp. Therap. 206: 115-122,
1978.
17.
Lokhandwala, M.F.: Pharmacological analysis of the tachycardia produced by
histamine and specific H1- and H2-receptor agonists in anesthetized dogs. Europ. J.
Pharmacol. 51: 351-359, 1978.
18.
Jandhyala, B.S., Washington, G.F. and Lokhandwala, M.F.: Influence of inhibition of
angiotensin converting enzyme with SQ-14225 on the arterial blood pressure of
mongrel dogs. Res. Comm. Chem. Pathol. Pharmacol. 22: 257-265, 1978.
19.
Lokhandwala, M.F., Amelang, E. and Buckley, J.P: Facilitation of cardiac
sympathetic function by angiotensin II: Role of presynaptic angiotensin receptors,
Europ. J. Pharmacol. 52: 405-409, 1978.
20.
Lokhandwala, M.F. and Jandhyala, B.S.: The role of sympathetic nervous system in
the vascular actions of dopamine, J. Pharmacol. Exp. Therap. 210: 120-126, 1979.
21.
Jandhyala, B.S., Lokhandwala, M.F., Nandiwada, P. and Buckley, J.P.: Circulatory
effects of chronic administration of angiotensin II into the cerebrolateral ventricles of
dogs: Studies on the development of an experimental model of hypertension,
Hypertension, 1: 219-277, 1979.
22.
Lokhandwala, M.F.: Analysis of the effects of bromocriptine on blood pressure and
sympathetic nerve function, Europ. J. Pharmacol. 56: 253- 256, 1979.
23.
Hardey, D.W. and Lokhandwala, M.F.: Influence of prazosin on cardiac reflex
function, Europ. J. Pharmacol. 57: 25l-254, 1979.
24.
Lokhandwala, M.F.: Evidence for a neurogenic mechanism in dopmine induced
depressor response in the anesthetized dog, Ind. J. Pharmacol. 11: 101-105, 1979.
25.
Jandhyala, B.S., Nandiwada, P., Buckley, J.P. and Lokhandwala, M.F.: Studies on the
mechanism of the hypotensive action of SQ-14225, an angiotensin converting enzyme
inhibitor in anesthetized dogs. Res. Comm. Chem. Pathol. Pharmacol. 25: 429-446,
1979.
26.
Jandhyala, B.S., Lokhandwala, M.F. and Buckley, J.P.: Circulatory effects of chronic
administration of angiotensin-II into the lateral cerebroventricles of dogs, Proc. West.
Pharmacol. Soc. 22: 231-233, 1979.
27.
Lokhandwala, M.F. and Jandhyala, B.S.: Sympathetic nerve function and renal
hemodynamics during hemorrhage: Role of pre- and post-synaptic interactions between
angiotensin II and prostaglandins. J. Pharmacol. Exp. Therap. 211: 539-545, 1979.
28.
Lokhandwala, M.F., Tadepalli, A.S. and Jandhyala, B.S.: Cardiovascular actions of
bromocriptine: Evidence for a neurogenic mechanism. J. Pharmacol. Exp. Therap. 211:
620-625, 1979.
29.
Lokhandwala, M.F.: Inhibition of cardiac sympathetic neurotransmission by
adenosine, Europ. J. Pharmacol. 60: 353-357, 1979.
33
30.
Hamed, A.T., Lokhandwala, M.F. and Jandhyala, B.S.: Relationship between plasma
renin activity and hypotensive effect of captopril in dogs. Res. Comm. Chem. Pathol.
Pharmacol. 28: 195-204, 1980.
31.
Nandiwada, P.A., Lokhandwala, M.F. and Jandhyala, B.S.: Modulation by histamine
of peripheral vagal transmission in anesthetized mongrel dogs. Europ. J. Pharmacol.
63: 281-286, 1980.
32.
Martinez, A.A. and Lokhandwala, M.F.: Evidence for a presynaptic inhibitory action
of 5-hydroxytryptamine on sympathetic neurotransmission to the myocardium. Europ.
J. Pharmacol. 63: 303-311, 1980.
33.
Ekas, R.D. and Lokhandwala, M.F.: Sympathetic nerve function and vascular
reactivity in DOCA-salt hypertensive rats. Amer. J. Physiol. 239: R303-R308, 1980.
34.
Hom, G.J. and Lokhandwala, M.F.: Effect of dipyridamole on sympathetic nerve
function: Role of adenosine and presynaptic purinergic receptors. J. Cardiovasc.
Pharmacol. 3:391-401, 1981.
35.
Hamed, A.T. and Lokhandwala, M.F.: Control of hindlimb vascular resistance and
vascular responsiveness in DOCA-salt hypertensive dogs. Clin. Exp. Hypertension. 3:
85-101, 1981.
36.
Hom, G.J. and Lokhandwala, M.F.: Presynaptic inhibition of vascular sympathetic
neurotransmission by adenosine. Europ. J. Pharmacol. 69: 101-106, 1981.
37.
Barrett, R.J. and Lokhandwala, M.F.: Presynaptic dopamine receptor stimulation in
the cardiovascular actions of lergotrile. J. Pharmacol. Exp. Therap. 217: 660-665,
1981.
38.
Hamed, A.T., Lokhandwala, M.F. and Jandhyala, B.S.: Effect of bromocriptine on
cardiac function and coronary blood flow. J. Cardiovasc. Pharmacol. 3: 636-646, 1981.
39.
Jandhyala, B.S., Boe, A.M., Adamski, S.W. and Lokhandwala, M.F.: Studies on the
effects of histamine on cholinergic transmission to the heart and vasculature in the
anesthetized cats. Arch. Int. Pharmacodyn. Therap. 249: 221-228, 1981.
40.
Hamed, A.T., Lokhandwala, M.F. and Jandhyala, B.S.: Comparative evaluation of the
factors regulating vascular resistance in dogs, anesthetized with morphine-chloralose or
pentobarbital. Arch. Int. Pharmacodyn.Therap. 249: 264-274, 1981.
41.
Buckley, J.P., Lokhandwala, M.F., Steenberg, M.L., Francis, J.S. and Tadepalli, A.S.:
Cardiovascular effects of chronic intraventricular administration of angiotensin II in
dogs. Clin. Exp. Hypertension, 3: 1001-1018, 1981.
42.
Eikenburg, D.C., Ekas, R.D. and Lokhandwala, M.F.: Strain differences in the
facilitatory action of angiotensin on noradrenergic transmission in the rat mesentery.
Clin. Exp. Hypertension, 3: 1039-1051, 1981.
43.
Hamed, A.T., Jandhyala, B.S., Ginos, J.Z. and Lokhandwala, M.F.: Presynaptic
dopamine receptors and alpha-adrenoceptors as mediators of the bradycardic action of
N-n-propyl-N-n-butyldopamine. Europ. J. Pharmacol. 74: 83-90, 1981.
34
44.
Ekas, R.D. and Lokhandwala, M.F.: Sympathetic nerve function and vascular
reactivity in spontaneously hypertensive rats. Amer. J. Physiol. 241: R379-R384, 1981.
45.
Ekas, R.D., Steenberg, M.L., Eikenburg, D.C. and Lokhandwala, M.F.: Presynaptic
inhibition of sympathetic neurotransmission by adenosine in the rat kidney. Europ. J.
Pharmacol. 76: 301-307, 1981.
46.
Barrett, R.J. and Lokhandwala, M.F.: Circulatory and vestibular implications of
central angiotensin mechanisms in physiological adaptation to weightlessness. Medical
Hypothesis, 7:1415-1419, 1981.
47.
Barrett, R.J., Ginos, J.Z. and Lokhandwala, M.F.: Evaluation of peripheral dopamine
receptor and alpha-adrenoceptor blocking activity of sulpiride. Europ. J. Pharmacol.
79: 273-281, 1982.
48.
Augustine, S.J., Buckley, J.P., Tachikawa, S. and Lokhandwala, M.F.: Involvement
of central noradrenergic mechanisms in the rebound hypertension following clonidine
withdrawal. J. Cardiovasc. Pharmacol. 4: 449-455, 1982.
49.
Barrett, R.J. and Lokhandwala, M.F.: Dopaminergic inhibition of cardiac sympathetic
nerve function by pergolide. Europ. J. Pharmacol. 77: 79-83, 1982.
50.
Hamed, A. T. and Lokhandwala, M. F.: Impairment of neurally-mediated
vasoconscriction in DOCA-salt hypertensive dogs. Clin. Exp. Hypertension, A4: 867881, 1982.
51.
Barrett, R.J. and Lokhandwala, M.F.: Presynaptic dopamine receptor stimulation and
the antihypertensive action of pergolide in experimental neurogenic hypertension, Proc.
West. Pharmacol. Soc. 25: 39-42, 1982.
52.
Eikenburg, D.C., Ekas, R.D. and Lokhandwala, M.F.: Alterations in prejunctional
responsiveness to angiotensin II during the development of 2-kidney, 1-clip Goldblatt
hypertension in rats. J. Pharmacol. Exp. Therap. 223: 766-773, 1982.
53.
Ekas, R.D., Steenberg, M.L. and Lokhandwala, M.F.: Increased presynaptic alphaadrenoceptor mediated regulation of nopradrenaline release in spontaneously
hypertensive rats. Clin. Sci. 63: 309s-311s, 1982.
54.
Ekas, R.D., Steenberg, M.L. and Lokhandwala, M.F.: Increased norepinephrine
release during sympathetic nerve stimulation and its inhibition by adenosine in the
isolated perfused kidney of spontaneously hypertensive rats. Clin. Exp. Hypertension,
A5, 41-48, 1983.
55.
Augustine, S.J., Tachikawa, S., Lokhandwala, M.F. and Buckley, J.P.: Central alphaadrenergic control of blood pressure: Rebount hypertension following clonidine
withdrawal. Chest, 83S: 328S-331S, 1983.
56.
Hamed, A.T., Ginos, J.Z., Ekas, R.D., Jandhyala, B.S. and Lokhandwala, M.F.: Renal
hemodynamics in hemorrhagic hypotension: studies on the effects of pre- and
postjunctional dopamine receptor agonists. J. Cardiovasc. Pharmacol. 5: 207-212,
1983.
35
57.
Ekas, R.D., Jr., Steenberg, M.L., Woods, M.S. and Lokhandwala, M.F.: Presynaptic
alpha and beta-adrenoceptor stimulation and norepinephrine release in the
spontaneously hypertensive rat. Hypertension, 5, 198-204, 1983.
58.
Nath, R.G., Lokhandwala, M.F. and McCalden, T.A.: Evidence for presynaptic
dopaminergic inhibition of noradrenergic transmission in the rat portal vein. Proc.
West. Pharmacol. Soc. 26: 377-379, 1983.
59.
Peter, E.J., Eikenburg, D.C. and Lokhandwala, M.F.: Influence of the autonomic
nervous system in the hypotensive action of calcium antagonists in rats. Proc. West.
Pharmacol. Soc. 26: 329-331, 1983.
60.
Steenberg, M.L., Ekas, R.D., Jr. and Lokhandwala, M.F.: Effect of epinephrine on
norepinephrine release from rat kidney during symapthetic nerve stimulation. Europ. J.
Pharmacol. 93: 137-148, 1983.
61.
Dobbins, D.E., Adamski, S.W., Lokhandwala, M.F. and Grega, G.J.: Evidence that
serotonin receptors, but not alpha-adrenergic receptors as presynaptic mechanisms,
contribute to the cutaneous vasoconstriction produced by 5-hydroxytryptamine in
canine forelimbs. Circ. Res. 53: 473-481, 1983.
62.
Eikenburg, D. C. and Lokhandwala, M. F.: Effects of Captopril on vascular
noradrenergic transmission during the development of 2-kidney, 1-clip Goldblatt
hypertension in rats, J. Hypertension, 1: 115-122, 1983.
63.
Barrett, R.J. and Lokhandwala, M.F.: Central and peripheral dopamnergic
mechanisms in the cardiovascular action of pergolide in neurogenic hypertensive dogs.
Europ. J. Pharmacol. 96: 211-226, 1983.
64.
Jadhav, A.L., Willett, R.N., Sapru, H.N. and Lokhandwala, M.F.: Involvement of
central dopamine receptors in the hypotensive action of pergolide. NaunynSchmiedeberg's Arch. Pharmacol. 324: 28l-286, 1983.
65.
Sabouni, M. and Lokhandwala, M.F.: No evidence for the involvement of histamine
(H1 or H2) receptors in the hypotension and presynaptic inhibition of sympathetic
inhibition of sympathetic nerve function caused by LY-141865 in dogs. Europ. J.
Pharmacol. 97: 145-149, 1984.
66.
Lokhandwala, M.F. and Steenberg, M.L.: Selective activation by LY-41865 and
apomorphine of presynaptic dopamine receptors in the rat kidney and influence of
stimulation parameters in the action of dopamine. J. Pharmacol. Exp. Therap. 228:
161-167, 1984.
67.
Lokhandwala, M.F., Kivlighn, S.D. and Jandhyala, B.S.: Characterization of
neurogenic vasodilatation elicited by central dopamine receptor stimulation with
pergolide. J. Pharmacol. Exp. Therap. 228: 696-703, 1984.
68.
Grega, G.J., Barrett, R.J., Adamski, S.W. and Lokhandwala, M.F.: Effects of
dopamine and SKF 82526, a selective DA1-receptor agonist, on vascular resistances in
the canine forelimb. J. Pharmacol. Exp. Therap. 229: 696-703, 1984.
69.
Lokhandwala, M.F. and Steenberg, M.L.: Evaluation of the effects of SKF 82526 and
LY 171555 on presynaptic (DA2) and postsynaptic (DA1) dopamine receptors in rat
kidney. J. Auton. Pharmacol.4: 273-277, 1984.
36
70.
Lokhandwala, M.F., Sabouni, M. and Jandhyala, B.S.: Cardiovascular actions of an
experimental antitumor agent, homoharringtonine, in anesthetized dogs. Drug Develop.
Res. 5: 147-163, 1985.
71.
Adamski, S.W., Dobbins, D.E., Lokhandwala, M.F. and Grega, G.J.: Effects of
dopamine and vasopressin on histamine-induced increases in macromolecular
permeability in the canine forelimb. Microcirc. Endo. and Lymph, 2: 27-39, 1985.
72.
Peter, E.J., Steenberg, M.L., Lokhandwala, M.F., Jandhyala, B.S. and Eikenburg,
D.C.: Influence of felodipine and verapamil on the sympathetic transmitter release and
on the pre and postjunctional effects of exogenous norepinephrine in the perfused rat
kidney. Drugs, 29 (Suppl.2) 198-204, 1985.
73.
Lokhandwala, M.F., Watkins, H.O., Sabouni, M.H. and Alkadhi, K.A.:
Pharmacological analysis of the actions of SKF 82526 on cardiovascular dopamine
receptors. J. Pharmacol. Exp. Therap. 234: 337-344, 1985.
74.
Lokhandwala, M.F. and Sabouni, M.H.: Ganglionic dopamine receptors as mediators
of the inhibition of neurogenic vasoconstriction produced by fenoldopam. J. Auton.
Pharmacol. 5: 301-306, 1985.
75.
Sengupta, S. and Lokhandwala, M.F.: Characterization of the hypotensive actions of
dopamine receptor agonists fenoldopam and quinpirole in anesthetized rats. J. Auton.
Pharmacol. 5: 286-295, 1985.
76.
Sabouni, M. H., Alkadhi, K. A. and Lokhandwala, M. F.: Pharmacological
characterization of dopamine receptors in the stellate ganglia with selective DA1 and
DA2 receptor agonists and antagonists. J. Pharmacol. Exp. Therap. 236: 65-70, 1986.
77.
Alkadhi, K. A., Sabouni, M. H., Ansari, A. F. and Lokhandwala, M. F.: Activation of
DA1 receptors by dopamine or fenoldopam increases cyclic-AMP levels in the renal
artery but not in the superior cervical ganglion of the rat. J. Pharmacol. Exp. Therap.,
238: 547-553, 1986.
78.
Hamed, A. T., Jandhyala, B. S. and Lokhandwala, M. F.: Evaluation of the role of
alpha-1 and alpha-2 adrenoceptors in the maintenance of neurogenic tone to the
hindlimb vasculature, J. Pharmacol. Exp. Therap., 238: 599-605, 1986.
79.
Sabouni, M. H., Alkadhi, K. A. and Lokhandwala, M. F.: Effect of dopamine receptor
activation on ganglionic transmission and cyclic-AMP levels in the stellate ganglia and
renal arteries of the dog. J. Pharmacol. Exp. Therap. 240: 93-98, 1987 .
80.
Sabouni, M. H., Alkadhi, K. A. and Lokhandwala, M. F.: Biochemical and
pharmacological characterization of ganglionic dopamine receptors, Clin. Exp.
Hyperten., A9: 873-887, 1987.
81.
Sowinski, B. A. and Lokhandwala, M. F.: Identification of dopamine receptor
subtypes in the hypotensive action of SK&F 85174 in anesthetized rats, J. Auton.
Pharmacol., 7: 105-109, 1987.
82.
Jandhyala, B. S., Lokhandwala, M. F., Kivlighn, S. D., Ansari, A. F., and DeFeo, M.
L.: Intracisternal administration of pergolide, a dopamine receptor agonist, triggers the
37
release of an inhibitor of ouabain-sensitive, sodium potassium-ATPase and enhances
vascular reactivity in anesthetized dogs, Clin. Sci.. 73: 183-188, 1987.
83.
DeFeo, M. L., Jadhav, A. L. and Lokhandwala, M. F.: Dietary sodium intake and
urinary dopamine and sodium excretion during the course of blood pressure
development in Dahl salt-sensitive and salt-resistant rats. Clin. Exp. Hyperten., A9:
2049-2060, 1987.
84.
Lokhandwala, M. F., Watkins, H. O. and Dlewati, A.: Different dopamine receptor
subtypes mediate neurogenic vasodilation producd by fenoldopam and SK&F 85174 in
the dog hindlimb. Europ. J. Pharmacol., 143: 383-390, 1987.
85.
Hegde, S. S. and Lokhandwala, M. F.: Involvement of cyclic-AMP in the hypotensive
response to fenoldopam but not to quinpirole in the anaesthetized rat. J. Auton.
Pharmacol., 8: 63-88, 1988.
86.
Steenberg, M. L., Lokhandwala, M. F. and Jandhyala, B. S.: Abnormalities in the
sodium transport as the causative factor for enhanced norepinephrine overflow in the
spontaneously hypertensive rat. Clin. Exp. Hyperten., A10: 833-841, 1988.
87.
Dlewati, A., Chelly, J. E., Doursout, M.-F. and Lokhandwala, M. F.: Renal, cardiac
and systemic hemodynamic effects of the dopamine receptor agonist SK&F 85174 in
anesthetized dogs. Drug Dev. Res., 16: 71-77, 1989.
88.
Dlewati, A., Watkins, H. O. and Lokhandwala, M. F.: Effects of SK&F 85174,
a DA-1/DA-2 receptor agonist, on pre- and postganglionic sympathetic
neurotransmission to the heart. Europ. J. Pharmacol., 164: 197-203, 1989.
89.
Hegde, S. S. and Lokhandwala, M. F.: Role of kidney dopamine in the natriuretic
response to volume expansion in rats. Hypertension, 13: 828-834, 1989.
90.
Hegde, S. S., Ricci, A., Amenta, F. and Lokhandwala, M. F.: Evidence from
functional and autoradiographic studies for the presence of tubular dopamine-1
receptors and their involvement in the renal effects of fenoldopam. J. Pharmacol. Exp.
Therap., 251: 1237-1245, 1989.
91.
Jadhav, A. L. and Lokhandwala, M. F.: Dietary sodium-induced changes in renal
noradrenergic and dopaminergic responses in rats. J. Human Hyperten., 4: 163-164,
1990.
92.
Grega, G. J., Staniciu, D., Murray, M. and Lokhandwala, M. F.: Effects of
dopexamine hydrochloride, a beta-adrenergic and dopaminergic agonist, on vascular
resistances, and flow distribution between cutaneous and skeletal muscle vasculatures.
Drug Dev. Res. 22: 69-77, 1991.
93.
Dlewati, A. and Lokhandwala, M. F.: Dose-response analysis of the effects of
fenoldopam, a dopamine-1 receptor agonist, on renal function. Drug Dev. Res. 22: 5968, 1991.
94.
Vyas, S. J., Apparsundaram, S., Ricci, A., Amenta, F. and Lokhandwala, M. F.:
Biochemical, autoradiographic and pharmacological evidence for the involvement of
tubular DA-1 receptors in the natriuretic response to dopexamine hydrochloride.
Naunyn- Schmiedeberg's Arch. Pharmacol., 343: 21-30, 1991.
38
95.
Amenta, F., Ricci, A., Napoleone, P., Vyas, S. J. and Lokhandwala, M. F.:
Anatomical localization of the binding and functional characterization of responses to
dopexamine hydrochloride in the rat mesenteric vasculature. Pharmacology, 42: 211222, 1991.
96.
Chen, C.-J., Apparsundaram, S. and Lokhandwala, M. F.: Intrarenally produced
angiotensin II opposes the natriuretic action of the DA-1 receptor agonist fenoldopam
in rats. J. Pharmacol. Exp. Ther., 256: 486-491, 1991.
97.
Hegde, S. S., Chen, C. J. and Lokhandwala, M. F.: Involvement of endogenous
dopamine and DA-1 receptors in the renal effects of atrial natriuretic factor in rats.
Clin. Exp. Hyperten., A13: 357-369, 1991.
98.
Chen, C. J. and Lokhandwala, M. F.: Role of endogenous dopamine in the natriuretic
response to various degrees of iso-osmotic volume expansion in rats. Clin. Exp.
Hyperten., A13:1117-1126, 1991.
99.
Jadhav, A. L., Ricci, A., Amenta, F. and Lokhandwala, M. F.: Renal dopamine and
changes in dopamine receptor ligand binding during high sodium intake. Clin. Exp.
Hyperten., A13:1371-1381, 1991.
100. Vyas, S. J., Eichberg, J. and Lokhandwala, M. F.: Characterization of receptors
involved in dopamine induced activation of phospholipase-C in rat renal cortex.
J.Pharmacol. Exp. Ther., 260:134-139, 1992.
101. Chen, C. J., Vyas, S. J., Eichberg, J. and Lokhandwala, M. F.: Diminished
phospholipase-C activation by dopamine in the kidney of spontaneously hypertensive
rats. Hypertension, 19:102-108, 1992.
102. Vyas, S. J., Jadhav, A. L., Eichberg, J. and Lokhandwala, M. F.: Dopamine receptor
mediated activation of phospholipase-C is associated with natriuresis during high
sodium intake. Amer. J. Physiol: Renal Physiol. 262: F494-F498, 1992.
103. Sakamoto, T. and Lokhandwala, M. F.: Effect of fenoldopam prodrug SK&F R105058 on renal function in rats. Drug Dev. Res., 26:79-88, 1992.
104. Chen, C. J. and Lokhandwala, M. F.: An impairment of renal tubular DA-1 receptor
function as the causative factor for diminished natriuresis to volume expansion in
spontaneously hypertensive rats. Clin. Exp. Hyperten., A14: 615-628, 1992.
105. Hegde, S. S. and Lokhandwala, M. F.: Stimulation of renal dopamine production
during acute volume expansion requires the presence of intact vagi but not renal nerves.
Clin. Exp. Hyperten., A14: 1169-1187, 1992.
106. Chen, C. J., Beach, R. E. and Lokhandwala, M. F.: Dopamine fails to inhibit sodium
pump in hypertensive rats. Hypertension, 21: 364-372, 1993.
107. Chen, C. J. and Lokhandwala, M. F.: Inhibition of Na+, K+ -ATPase in rat renal
proximal tubule by dopamine involves DA-1 receptor activation. NaunynSchmiedberg’s Arch. Pharmacol. 347: 289-295, 1993.
108. Chintala, M.S., Moore, R.J., Lokhandwala, M.F. and Jandhyala, B.S.: Evaluation of
the effects of dopexamine, a novel DA-1 receptor and beta-2 adrenoceptor agonist on
39
cardiac function and splanchnic circulation in a canine model of haemorrhagic shock.
Naunyn-Scmiedeberg’s Arch. Pharmacol. 347: 296-300, 1993.
109. Gopalakrishnan, S., Chen, C .J. and Lokhandwala, M .F.: Identification of
α1-adrenoceptor subtypes in the rat renal proximal tubules, Europ. J. Pharmacol, 250:
469-472, 1993.
110. Sakamoto, T., Chen, C .J. and Lokhandwala, M .F.: Lack of renal dopamine
production during acute volume expansion in Dahl salt-sensitive rats. Clin. Exp.
Hyperten., 16:197-206, 1994.
111. Sakamoto, T., Chen, C. J. and Lokhandwala, M. F.: Attenuation of adenylate cyclase
induced increases in renal sodium excretion by Dopamine (DA)-2 receptor agonist
SK&F 89124. J. Auton. Pharmacol. 14: 295-306, 1994.
112. Sakamoto, T., Chen, C. J. and Lokhandwala, M. F.: Contribution by bradykinin to the
natriuretic response to angiotensin cnverting enzyme inhibitor, ramiprilat in
spontaneously hypertensive rats. Naunyn-Schiemedeberg’s Arch. Pharmacol. 350: 8489, 1994.
113. Jacinto, S.M., Lokhandwala, M.F. and Jandhyala, B.S.:Studies on the phamacological
interventions to prevent oxygen free radical mediated toxicity; Effects of dopexamine, a
DA1 receptor and β2 adrenoceptor agonist. Naunyn-Schmiedeberg’s Arch. Pharmacol.
350: 277-283, 1994.
114. Gopalakrishnan, S. M., Chen, C. J. and Lokhandwala, M. F.: α1-Adrenoceptor
subtypes mediating stimulation of sodium, potassium-ATPase activity, and activation
of inositol trisphosphate and protein kinase C in rat renal proximal tubules.Europ. J.
Pharmacol. Mol. Pharmacol Sec. 288: 139-147, 1995.
115. Kansra, V., Chen,C.J. and Lokhandwala, M.F.: Dopamine causes stimulation of
protein kinase C in rat renal proximal tubules by activating dopamine D1 receptors.
Europ. J. Pharmacol. Mol. Pharmacol. Sec.289: 391-394, 1995.
116. Chen C. J. and Lokhandwala, M. F.: Potentiation by enalaprilat of fenoldopam-evoked
natriuresis is due to blockade of intrarenal production of angiotensin II in rats. NaunynSchmiedeberg’s Arch. Pharmacol. , 352: 194-200, 1995.
117. Kansra,V., Chen,C.J. and Lokhandwala, M.F.: Dopamine fails to stimulate protein
kinase C activity in renal proximal tubules of spontaneously hypertensive rats.
Clin.Exp. Hypertension, 17: 837-845, 1995.
118. Chen, C. J. and Lokhandwala, M. F.: Identification of α1-adrenoceptor subtypes
involved in the antinatriuretic response to intrarenal infusion of phenylephrine. Europ.J.
Pharmacol. 287: 1-6, 1995.
119. Jacinto, S.M., Lokhandwala, M.F. and Jandhyala, B.S.: Effect of pharmacological
interventions in the prevention of lipid peroxidation and respiratory depression induced
by oxygen free radicals in anesthetized rats. Free Radical Biol. and Med. 21: 791-799,
1996.
120. Hussain,T. and Lokhandwala, M. F.: Altered arachadonic acid metabolism contributes
to the failure of dopamine to inhibit Na,K-ATPase in kidney of spontaneously
hypertensive rats. Clin Exp Hypertension, 18: 963-974, 1996.
40
121. Hussain, T. and Lokhandwala, M. F. : Renal dopamine-1 receptor coupling with Gs
and Gq/11proteins in spontaneously hypertensive rats. Amer. J. Physiol: Renal
Physiol.272: F339-F346, 1997.
122. Pedemonte, C.H., Pressley, T. A., Lokhandwala, M. F. and Cinelli, A. R.: Regulation
of Na,K-ATPase transport activity by protein kinase C. J. Membrane Biol.. 155: 219227, 1997.
123. Hussain, T., Abdul-Wahab, R. and Lokhandwala, M. F.: Bromocriptine stimulates
Na+,K+-ATPase in renal proximal tubules via cAMP pathway. Europ. J. Pharmacol.
231: 259-263, 1997.
124. Kansra, V., Hussain, T. and Lokhandwala, M. F.: Alterations in DA1 receptor and Gproteins in renal proximal tubules of old rats. Amer. J. Physiol: Renal Physiol. 273:
F53-F59, 1997.
125. Pedemonte, C.H., Pressley, T.A., Cinelli, A.R. and Lokhandwala, M.F.: Stimulation
of protein kinase C rapidly reduces intracellular Na+ concentration via activation of
Na+ -pump in OK cells. Mol. Pharmacol. 52: 88-97, 1997.
126. Bharatula, M., Hussain, A. and Lokhandwala, M. F.: Angiotensin II AT1
receptor/signaling mechanisms in the biphasic effect of the peptide on proximal tubular
Na+, K+ -ATPase. Clin. Exp. Hypertension, 20:465-480, 1998.
127. Hussain, T., Abdul-Wahab, R., Kotak, D. and Lokhandwala, M.F.: Bromocriptine
regulates angiotensin II response on sodium pump in proximal tubules. Hypertension,
32: 1054-1059, 1998.
128. Vieira~Coelho, M.A., Hussain,T., Kansra, V., Serraro, P., Guimares, J.T., Pestana, M.,
Soares-da-Silva, P. and Lokhandwala, M.F.: Aging, high salt intake and renal
dopaminergic activity in Fischer 344 rats. Hypertension, 34: 666-672, 1999.
129. Hussain, T., Beheray, S. and Lokhandwala, M.F.: Defective dopamine receptor
function in renal proximal tubules of obese Zucker rats. Hypertension, 34: 1091-1096,
1999.
130. Lokhandwala, M.F. and Hussain, T.: Defective renal dopamine D1-like receptor
signal transduction in obese hypertensive rats. Acta. Physiol. Scand. 168: 251-255,
2000.
131. Beheray, S., Kansra, V., Hussain, T. and Lokhandwala, M. F.: Diminished natriuretic
response to dopamine in old rats is due to an impaired D1-like receptor signaling
pathway. Kidney International, 58: 712-720, 2000.
132. Venkatakrishnan, U., Chen, C. and Lokhandwala, M. F.: The role of nitric oxide in the
natriuretic response to dopamine-1 receptor activation. Clin. Exp. Hypertension, 22:
309-324, 2000.
133. Beheray, S., Hussain, T. and Lokhandwala, M. F.: Dopamine inhibits Na,H-exchanger
via D1-like receptor-mediated stimulation of protein kinase A in renal proximal
tubules. Clin Exp Hypertension, 22: 635-644, 2000.
41
134. Asghar, M., Kansra, V., Hussain, T. and Lokhandwala, M.F.: Hyperphos-phorylation
of Na-pump contributes to defective renal dopamine response in old rats. J. Amer. Soc.
Nephrol. 12: 226-232, 2001.
135. Asghar, M., Hussain, T. and Lokhandwala, M.F.: Activation of dopamine D1-like
receptor causes phosphorylation of alpha-1 subunit of Na,K ATPase in rat renal
proximal tubules. Europ. J. Pharmacol. 411: 61-66, 2001.
136. Narkar, V.A., Hussain, T., Pedemonte, C. and Lokhandwala, M.F.: Dopamine D2-like
receptor activation causes mitogenesis via p44/42 MAPK in opposum kidney cells. J.
Amer. Soc. Nephrol , 12: 1844-1852, 2001.
137. Vieira-Coelho, M.A., Serrao, P., Hussain,T., Lokhandwala, M.F., and Soares-daSilva, P.: Salt intake and intestinal dopaminergic activity in adult and old Fischer 344
rats. Life Scinces, 69: 1957-1968, 2001.
138. Ricci, A., Amenta, F., Bronzetti, E., Felici, A., Hussain, T., and Lokhandwala, M.F.:
Age-related changes of dopamine receptor protein immunoreactivity in the rat
mesenteric vascular tree. Mech of Aging and Develop, 123: 537-546, 2002.
139. Hussain, T., Becker, M., Beheray, S. and Lokhandwala, M. F.: Dopamine fails to
inhibit Na,H-exchanger in proximal tubules of obese zucker rats. Clin.Exp.
Hypertension 23: 591-601, 2001.
140. Narkar,V., Hussain, T. and Lokhandwala, M. F.: Role of tyrosine kinase and p44/42
MAPK in D2-like receptor-mediated stimulation of Na,K-.ATPase in kidney. Amer. J.
Physiol: Renal Physiol. 282: F697-F702, 2002.
141. Lucas-Teixeira , V.A., Hussain, T., Serrao, P., Soares-da-Silva, P. and Lokhandwala,
M.F.: Intestinal dopaminergic activity in obese and lean Zucker rats: Response to high
salt intake. Clin. Exp. Hypertension, 24: 383-396, 2002.
142. Asghar, M., Hussain,T. and Lokhandwala, M.F.: Higher basal phosphorylation of
D1A receptors in the proximal tubules of old Fischer rats. Amer. J. Physiol: Renal
Physiol. 283: F350-F355, 2002.
143. Narkar, V., Hussain, T. and Lokhandwala, M.F.: Activation of D2-like dopamine
receptors causes recruitment of tyrosine phosphorylated Na, K- ATPase alpha 1subunits in the kidney. Amer. J. Physiol: Renal Physiol. 283: F1290-F1295, 2002.
144. Umrani, D. M., Banday, A. A., Hussain, T. and Lokhandwala, M. F.: Rosiglitazone
Treatment Restores Renal Dopamine Receptor Function in Obese Zucker Rats.
Hypertension, 40: 880-885, 2002.
145. Becker, M., Umrani, D., Lokhandwala, M.F. and Hussain, T.: Increased renal
angiotensin II AT1 receptor function in obese Zucker rat. Clin. Exp. Hypertension, 25:
59-71, 2003.
146. Banday,A.A., Asghar, M., Hussain, T. and Lokhandwala, M.F.: Dopamine-mediated
inhibition of renal Na,K-ATPase is reduced by insulin. Hypertension, 41: 1353-1358,
2003.
42
147. Asghar, M., Hussain, T. and Lokhandwala, M.F.: Over-expression of PKC-βI and –δ
contributes to higher PKC activity in the proximal tubules of old Fischer 344 rats.
Amer. J. Physiol: Renal Physiol. 285: F1100-F1107, 2003.
148. Marwaha, A. and Lokhandwala, M.F: Diminished natriuretic response to dopamine
D1-receptor agonist, SKF-38393 in Obese Zucker rats. Clin. Exp. Hypertension, 25:
509-516, 2003.
149. Marwaha, A., Banday, A.A. and Lokhandwala, M.F.: Reduced renal dopamine D1
receptor function in streptozotocin-induced diabetic rats. Amer.J.Physiol: Renal
Physiol. 286: F451-F457, 2004.
150. Trivedi, M., Marwaha, A. and Lokhandwala, M.F.: Rosiglitazone restores recruitment,
G-protein coupling and function of renal dopamine D1 receptors in obese Zucker rats.
Hypertension, 43: (Part2): 376-382, 2004.
151. Asghar, M. and Lokhandwala, M.F.: Antioxidant supplementation normalizes
elevated protein kinase C activity in proximal tubules of old rats. Exp. Biol. Med 229:
27-275, 2004.
152. Narkar, V., Kunduzova, O., Hussain, T., Cambon, C., Parini, A. and Lokhandwala,
M.F.: Dopamine D2-like receptor agonist bromocriptine protects against ischemiareperfusion injury in rat kidney. Kidney International, 66: 634-640, 2004.
153. Banday, A. A., Hussain, T. and Lokhandwala, M. F.: Renal dopamine D1 receptor
function is aquired and not inherited in obese Zucker rats. Amer. J. Pysiol: Renal
Physiol. 287: F109-F116, 2004.
154. Trivedi, M., Narkar, V. A., Hussain, T. and Lokhandwala, M. F.: Dopamine recruits
D1A receptors to Na-K-ATPase-rich caveolar plasma membranes in rat renal proximal
tubules. Amer. J. Physiol: Renal Physiol. 287: F921-F931, 2004.
155. Trivedi, M. and Lokhandwala, M.F.: Rosiglitazone restores renal D1A receptor-Gsprotein coupling by reducing receptor hyperphosphorylation in obese rats. Amer J.
Physiol: Renal Physiol. 289: F298-F304, 2005.
156. Banday, A.A., Marwaha, A. and Lokhandwala, M.F.: Tempol reduces oxidative
stress, improves insulin sensitivity, decreases renal dopamine D1 receptor
hyperphosphorylation and restores D1 recptor-G protein coupling and function in obese
Zucker rats. Diabetes, 54: 2219-2226, 2005.
157. Asghar, M. Banday, A. A., Fardoun, R. and Lokhandwala, M.F.: Hydrogen peroxide
causes uncoupling of dopamine D1 receptors from G-proteins via a mechanism
involving PKC and GRK2. Free Radical Biol. & Med. 40: 13-20, 2006.
158. Marwaha, A. and Lokhandwala, M. F.: Tempol reduces oxidative stress and restores
renal dopamine D1-like receptor G-protein coupling and function in hyperglycemic
rats. Amer J Physiol: Renal Physiol. 291: F58-F66, 2006.
159. Asghar, M. and Lokhandwala, M.F.: Antioxidant tempol decreases age-related
increase in insulin resistance in old Fischer 344 rats. Clin Exp Hypertension, 28: 533541, 2006.
43
160. Fardoun, R. Z., Asghar, M. and Lokhandwala, M.F.: Role of Oxidative Stress in
Defective Renal Dopamine D1 Receptor- G-Protein Coupling and Function in Old
Fischer 344 Rats. Amer J Physiol: Renal Physiol. 291: F945-F951, 2006.
161. Banday, A.A. and Lokhandwala, M.F.: Defective renal dopamine D1 receptor
function contributes to hyperinsulinemia mediated hypertension. Clin Exp
Hypertension, 28: 695-705, 2006.
162. Banday, A.A., Fazili, F.R., Marwaha, A.A. and Lokhandwala, M.F.: Mitogenactivated protein kinase upregulation reduces renal D1 receptor affinity and G-protein
coupling in obese rats. Kidney International, 71: 397-406, 2007.
163. Fardoun, R. Z., Asghar, M. and Lokhandwala, M.F.: Role of NFkB in oxidative
stress-induced defective dopamine D1 receptor signaling in renal proximal tubules of
Sprague Dawley rats. Free Radical Biol. & Med. 42: 756-764, 2007.
164. Banday, A. A., Muhammad, A.B., Fazili, F.R. and Lokhandwala, M.F.: Mechanism of
oxidative stress induced increase in salt sensitivity and development of hypertension in
Sprague Dawley rats, Hypertension, 49[part 2]: 664-667, 2007.
165. Banday, A. A., Fazili, F. R. and Lokhandwala, M. F.: Oxidative stress causes renal
dopamine D1 receptor dysfunction and hypertension via mechanisms involving nuclear
factor-kB and protein kinase C. J Amer Soc Nephrol, 18: 1446-1457, 2007.
166. Asghar, M., Monjok, E., Kouamou, G., Ohia, S.E., Bagchi, D. and Lokhandwala,
M.F.: Super CitriMax (HCA-SX) attenuates increases in oxidative stress, inflammation,
insulin resistance and body weight in developing obese Zucker rats. Mol. Cell.
Biochem. 304: 93-99, 2007.
167. Banday, A.A. and Lokhandwala, M.F.: Oxidative stress reduces renal dopamine D1
receptor-Gq/11α G protein-phospholipase C signaling involving G protein-coupled
receptor kinase 2. Amer J Physiol: Renal, 293: F306-F315, 2007.
168. Banday, A.A., Fazili, F.R. and Lokhandwala, M.F.: Insulin Causes Renal Dopamine
D1 Receptor Desensitization via GRK2-mediated Receptor Phosphorylation Involving
Phosphatidylinositol3-Kinase and Protein kinase C. Amer J Physiol: Renal, 293: F877F884, 2007.
169. Asghar, M., George, L. and Lokhandwala, M.F.: Exercise decreases oxidative
stress and inflammation and restores renal dopamine D1 receptor function in old
rats. Amer J Physiol: Renal Physiol. 293: F914-F919., 2007.
170. Banday, A.A., Lau, Y-S and Lokhandwala, M.F.: Oxidative stress causes renal
dopamine D1 receptor dysfunction and salt-sensitive hypertension in SpragueDawley Rats. Hypertension, 51: 367- 375, 2008.
171. Banday, A.A. and Lokhandwala, M.F.: Oxidative stress-induced renal angiotensin
AT1 receptor upregulation causes increased stimulation of sodium transporters and
hypertension. Amer J Physiol: Renal Physiol., 295: F698-F706, 2008.
172. Asghar, M., Chillar, A. and Lokhandwala, M.F.: Renal proximal tubules from old
Fischer 344 rats grow into epithelial cells in culture and exhibit inceresed oxidative
44
stress and reduced D1 receptor function. Amer J Physiol: Cell Physiol. 295: C1326C1331, 2008.
173. Banday, A. A. and Lokhandwala, M.F.: Loss of biphasic effect on Na/K-ATPase
activity by angiotensin II involves defective angiotensin typr 1 receptor-nitric oxide
signaling. Hypertension, 52: 1099-1105, 2008.
174. Banday, A.A. and Lokhandwala, M.F.: Inhibition of natriuretic factors increases
blood pressure in rats. Amer J Physiol: Renal Physiol., 297: F397-F402, 2009.
175. George, L., Lokhandwala, M.F. and Asghar, M: Exercise activates redox sensitive
transcription factors and restores renal D1 receptor function in old rats. Amer J
Physiol: Renal Physiol., 297: F1174-1180, 2009.
176. Asghar, M., Chugh, G. and Lokhandwala, M.F.: Inflammation compromises renal
dopamine D1 receptor function in rats. Amer J Physiol: Renal Physiol., 297: F1543F1549, 2009.
177. Muhammad, A.B., Lokhandwala, M.F. and Banday, A.A.: Exercise reduces
oxidative stress but does not alleviate hyperinsulinemia or renal dopamine D1
receptor dysfunction in obese Zucker rats. Amer J Physiol: Renal Physiol, 300:F98F104, 2011.
178. Chugh, G., Lokhandwala, M.F. and Asghar, M.: Oxidative stress alters renal D1
and AT1 receptor functions and increases blood pressure in old rats. Amer J
Physiol: Renal Physiol, 300: F133-F138, 2011.
179. Banday, A.A. and Lokhandwala, M.F.: Oxidative stress causes renal angiotensin
II type 1 receptor upregulation, Na+/H+ exchanger 3 overstimulation and
hypertension. Hypertension, 57: 452-459, 2011.
180. Bhatt, S., Lokhandwala, M.F. and Banday, A.A.: Resveratrol prevents endothelial
nitric oxide synthase uncoupling and attenuates development of hypertension in
spontaneously hypertensive rats. Europ. J. Pharmacol., in press, 2011.
181. Banday, A.A. and Lokhandwala, M.F.: Angiotensin II-Mediated Biphasic
Regulation of Proximal Tubular Na+/H+ Exchanger 3 is Impaired during Oxidative
Stress. Amer J Physiol: Renal Physiol, in press, 2011.
Abstracts
1.
Lokhandwala, M.F. and Jandhyala, B.S.: Effect of hexamethonium on cardiac rate in
conscious dogs. Fed. Proc. 32: 800, 1973.
2.
Lokhandwala, M.F., Vollmer, R., Jandhyala, B.S. and Buckley, J.P.: The effect of
chronic administration of guanethidine on sympathetic neuronal function in dogs. Fed.
Proc. 33:470, 1974.
45
3.
Cavero, I., Lokhandwala, M.F., Jandhyala, B.S. and Gerold, M: Effects of (-)-∆9transtetrahydrocannabinol (THC) on venous return in dogs. Experientia, 30: 694, 1974.
4.
Lokhandwala, M.F.: Effects of methyldopa on regional hemodynamics and
sympathetic nerve function in the dog. Fed. Proc. 34: 817, 1975.
5.
Lokhandwala, M.F., Buckley, J.P. and Jandhyala, B.S.: Further studies on the
mechanism of action of methyldopa mongrel dogs. Pharmacologist 17: 224, 1975.
6.
Lokhandwala, M.F. and Buckley, J.P.: Studies on the role of various factors in the
antihypertensive action of propranolol. Fed. Proc. 35: 771, 1976.
7.
Lokhandwala, M.F. and Buckley, J.P.: Presynaptic modulation of sympathetic
transmission to the myocardium by various catecholamines. Circulation, 54: II-1977.
8.
Buckley, J.P. Singh, S., Jandhyala, B.S. and Lokhandwala, M.F.: Central effects of
angiotensin II on renal hemodynamics, plasma renin activity and water and electrolyte
excretion. Fed. Proc. 36: l377, 1977.
9.
Lokhandwala, M.F.: Studies on the mechanism of L-dopa induced impairment of
sympathetic nervous transmission in anesthetized dogs. Fed. Proc. 36: 3671, 1977.
10.
Jandhyala, B.S., Pariani, H.K. and Lokhandwala, M.F.: The role of central alphaadrenergic receptors in the hypotension and bradycardia produced by ∆9tetrahydrocannabinol in the anesthetized cat. Fed. Proc. 36: 3575, 1977.
11.
Lokhandwala, M.F.: Effect of histamine on sympathetic nerve function in mongrel
dogs. Fed. Proc. 37: 2064, 1978.
12.
Amelang, E., Buckley, J.P. and Lokhandwala, M.F.: Evidence for a facilitatory effect
of angiotensin II on sympathetic nerve function to the myocardium in mongrel dogs.
Pharmacologist, 20: 310, 1978.
13.
Hardey, D.W. and Lokhandwala, M.F.: Studies on the mechanism of cardiovascular
actions of prazosin in the anesthetized dog. Pharmacologist 20: 233, 1978.
14.
Jandhyala, B.S., Nandiwada, P., Buckley, J.P. and Lokhandwala, M.F.: Relationship
between inhibition of angiotensin I converting enzyme (ACE) and hypotensive activity
of SQ-14225 in dogs. Pharmacologist, 20: 582, 1978.
15.
Buckley, J.P., Lokhandwala, M.F., Amelang, E., Nandiwada, P. and Jandhyala, B.S.:
Circulatory effects of chronic intraventricular administration of angiotensin II in dogs.
Circulation, 57 and 58: Suppl-II- 143, 1978.
16.
Martinez, A.A. and Lokhandwala, M.F.: Effect of 5-hydroxytryptamine on
sympathetic nerve function. Fed. Proc. 38: 1963, 1979.
17.
Buckley, J.P., Saelens, D., Lokhandwala, M.F. and Jandhyala, B.S.: Cardiovascular
effects of chronic intraventricular administration of angiotensin II in dogs. Fed. Proc.
38: 2364, 1979.
18.
Lokhandwala, M.F., Washington, G.F. and Jandhyala, B.S.: The role of presynaptic
dopamine receptors in the cardiovascular actions of bromocriptine. Pharmacologist, 21:
20, 1979.
46
19.
Nandiwada, P., Lokhandwala, M.F. and Jandhyala, B.S.: Modification by histamine of
vagally mediated bradycardic effects in the anesthetized mongrel dog. Pharmacologist,
21: 632, 1979.
20.
Lokhandwala, M.F. and Jandhyala, B.S.: The role of angiotensin II and
prostaglandins in control of renal hemodynamics during hemorrhage. Physiologist, 22:
78, 1979.
21.
Nandiwada, P., Lokhandwala, M.F. and Jandhyala, B.S.: Evidence for the role of H2
receptor in the modulation of peripheral vagal transmission in pentobarbital
anesthetized dog. Physiologist, 22: 93, 1979.
22.
Ekas, R.D. and Lokhandwala, M.F.: Sympathetic nerve function and vascular
reactivity in DOCA-salt hypertension. Proc. SW Sec. Soc. Exp. Biol. Med., 1:30, 1979.
23.
Lokhandwala, M.F.: Involvement of presynaptic dopamine receptors in the
cardiovascular actions of bromocriptine. Proc. SW Sec. Soc. Exp. Biol. Med. l: 47,
1979.
24.
Augustine, S.J. and Lokhandwala, M.F.: Alterations in responses of pre- and
postsynaptic alpha-adrenoceptors during withdrawal of chronic clonidine treatment in
rats, Fed. Proc. 39, 699, 1980.
25.
Hamed, A.T. and Lokhandwala, M.F.: The effect of DOCA-salt hypertension on
hindlimb vascular resistance in dogs. Fed. Proc. 39: 1210, 1980.
26.
Barrett, R.J. and Lokhandwala, M.F.: Involvement of a dopaminergic mechanism in
the cardiovascular actions of lergotrile in dos. Fed. Proc. 39: 1860, 1980.
27.
Hom, G.J. and Lokhandwala, M.F.: The effect of adenosine on sympathetic nerve
function: Influence of dipyridamole and theophylline. Fed. Proc. 39: 3111, 1980.
28.
Ekas, R.D. and Lokhandwala, M.F.: No evidence for alterations in norepinephrine
release in DOCA-salt hypertensive rats. Fed. Proc. 39: 4832, 1980.
29.
Lokhandwala, M.F. and Ekas, R.D.: Evidence for an increase in norepinephrine
release in the spontaneously hypertensive rat. Pharmacologist, 22: 34, 1980.
30.
Buckley, J. P., Lokhandwala, M.F., Francis, J.S., Tadepalli, A.S., Steenberg, M.L. and
Jandhyala, B.S.: Effectss of chronic intraventricular administration of angiotensin II in
dogs. VIIth Scientific Meeting of the International Society of Hypertension. Abst.#15,
1980.
31.
Ekas, R.D. and Lokhandwala, M.F.: Vascular hyperresponsiveness in the
spontaneously hypertensive rat: Evidence for an increase in norepinephrine release.
VIIth Scientific Meeting of the International Society of Hypertension. Abst. #29, 1980.
32.
Adamski, S., Francis, J.S., Buckley, J.P. and Lokhandwala, M.F.: Effects of
intraventricular administration of bepridil on cardiovascular hemodynamics of
anesthetized and conscious dogs. Neuroscience, Abst. 6: 164, 1980.
47
33.
Augustine, S.J. and Lokhandwala, M.F.: Characteristics and Mechanisms of clonidine
withdrawal syndrome in normotensive and spontaneously hypertensive rats. Fed. Proc.
40: 32, 1981.
34.
Ekas, R.D., Eikenburg, D.C., Steenberg, M.L. and Lokhandwala, M.F.: Presynaptic
regulation of endogenous norepinephrine release in the isolated perfused rat kidney.
Fed. Proc. 40: 106, 1981.
35.
Barrett, R.J. and Lokhandwala, M.F.: The role of alpha-adrenergic and dopamine
receptor activation in the cardiovascular effects of pergolide. Fed. Proc. 40: 315, 1981.
36.
Lokhandwala, M.F. and Barrett, R.J.: Mechanism of potentiation of responses to
cardiac nerve stimulation by sulpiride. Fed. Proc. 40, 316, 1981.
37.
Hamed, A.T., Jandhyala, B.S., Ginos, J.Z. and Lokhandwala, M.F.: Mechanism of
bradycardic action of N-n-propyl-N-n-butyl dopamine: Involvement of presynaptic
dopamine and alpha adrenoceptors. Fed. Proc. 40, 453, 1981.
38.
Eikenburg, D.C., Ekas, R.D. and Lokhandwala, M.F.: Presynaptic action of
angiotensin II and vascular reactivity during development of 2-kidney Gold-blatt
hypertension. Fed. Proc. 40: 1729, 1981.
39.
Augustine, S.J., Buckley, J.P., Tachikawa, S. and Lokhandwala, M.F.: Involvement
of central noradrenergic mechanisms in rebound hypertension precipitated by clonidine
withdrawal. VIIIth Scientific Meeting of the International Society of Hypertension.
Abst. #31, 1981.
40.
Chelly, J., Lokhandwala, M.F., Huchet, A.M., Doursoud, M.F., Schmitt, H. and
Buckley, J.P.: L-glutamate induces neurogenic hypertension in dogs. VIIIth Scientific
Meeting of the International Society of Hypertension. Abst. #77, 1981.
41.
Barrett, R.J. and Lokhandwala, M.F.: Pharmacologic and therapeutic implications of
presynapticc dopamine receptor stimulation in experimental hypertension. IXth
Scientific Meeting of the International Society of Hypertenison. Abst. #33, 1982.
42.
Eikenburg, D.C. and Lokhandwala, M.F.: In vivo modulation of vascular sympathetic
neurotransmission by angiotensin II during the development of 2-kidney Goldblatt
hypertension. IXth Scientific Meeting of the International Society of Hypertension.
Abst. #104, 1982.
43.
Ekas, R.D., Steenberg, M.L. and Lokhandwala, M.F.: Increased presynaptic alphaadrenoceptor-mediated regulation of norepinephrine release in the isolated perfused
kidney of spontaneously hypertensive rats. IXth Scientific Meeting of the International
Society of Hypertension. Abst. #105, 1982.
44.
Steenberg, M.L. Ekas, R.D. and Lokhandwala, M.F.: Facilitation of norepinephrine
release by beta-adrenoceptor agonists during sympathetic nerve stimulation in the
isolated perfused rat kidney. Fed. Proc. 41: 4592, 1982.
45.
Hamed, A.T., Jandhyala, B.S. and Lokhandwala, M.F.: Effects of dopamine receptor
agonists on renal and femoral hemodynamics following acute hemorrhagic hypotension
in anesthetized dogs. Fed. Proc. 41: 5834, 1982.
48
46.
Lokhandwala, M.F., Steenberg, M.L. and Ekas, R.D.: Alterations in presynaptic
alpha-adrenoceptor-mediated regulation of norepinephrine release in spontaneously
hypertensive rats. Fed. Proc. 41: 6274, 1982.
47.
Eikenburg, D.C. and Lokhandwala, M.F.: Lack of prejunctional adrenergic facilitation
by angiotensin II in 2-kidney Goldblatt hypertension. Fed. Proc. 41: 7694, 1982.
48.
Barrett, R.J. and Lokhandwala, M.F.: Central dopaminergic mechanisms in the
cardiovascular actions of intracisternally-administered pergolide. Fed. Proc. 41: 7694,
1982.
49.
Jadhav, A.L. and Lokhandwala, M.F.: Involvement of central and peripheral
dopaminergic mechanisms in the hypotensive and bradycardic effects of pergolide in
the rat. Pharmacologist, 24: 63, 1982.
50.
Ekas, R.D., Lokhandwala, M.F. and Steenberg, M.L.: Evidence for the presence of
presynaptic facilitatory beta-adrenoceptors on renal noradrenergic nerves. Brit. J.
Pharmacol. 77: 407P, 1982.
51.
Lokhandwala, M.F., Patel, U. P. and Jandhyala, B.S.: Central actions of pergolide on
neurogenic vascular tone in dogs. Fed. Proc. 42: 2777, 1983.
52.
Jadhav, A.L., Willette, R.N., Sapru, H.N. and Lokhandwala, M.F.: Centrallymediated inhibition of peripheral sympathetic nerve activity by pergolide. Fed. Proc.
42: 3382, 1983.
53.
Eikenburg, D.C. and Lokhandwala, M.F.: Influence of captopril on vascular
noradrenergic transmission in vivo in spontaneously hypertensive rats. Fed. Proc. 42:
5147, 1983.
54.
Steenberg, M.L., Peter, E., Eikenburg, D.C., Jandhyala, B.S. and Lokhandwala, M.F.:
Effects of felodipine on sympathetic transmitter release and vasoconstrictor responses
to exogenous norepinephrine in the isolated perfused rat kidney. Physiologist, 26: 8-15,
1983.
55.
Alkadhi, K.A., Sabouni, M.H. and Lokhandwala, M.F.: Characterization of dopamine
receptors in a mammalian sympathetic ganglion. Fed. Proc. 43: 4731, 1984.
56.
Sabouni, M.H. and Lokhandwala, M.F.: Effects of selective DAl- and DA2-receptor
agonists on responses to pre and postganglionic cardiac sympathetic nerve stimulation.
Fed. Proc. 43: 4732, 1984.
57.
Lokhandwala, M.F., Watkins, H. and Alkadhi, K.A.: Involvement of DA1-receptors in
the neurogenic vasodilation produced by SKF 82526 in the canine hindlimb. Fed. Proc.
43: 4733, 1984.
58.
Adamski, S.W., Grega, G.J. and Lokhandwala, M.F.: Effects of dopamine and SKF
82526 on forelimb vascular resistance in dogs anesthetized with pentobarbital. Fed.
Proc. 43: 4734, 1984.
59.
Peter, E.J., Eikenburg, D.C. and Lokhandwala, M.F.: Effects of calcium antagonists
on pre and postsynaptic noradrenergic mechanisms in the rat kidney. Fed. Proc. 43:
961, 1984.
49
60.
Peter, E.J., Eikenburg, D.C. and Lokhandwala, M.F.: Differential actions of calcium
antagonists on pre and postjunctional noradrenergic mechanisms in the perfused rat
kidney. Xth Scientific Meeting of the International Society of Hypertension. Abst. #694,
1984.
61.
Lokhandwala, M.F., Sabouni, M.H. and Alkadhi, K.A.: Dopaminergic inhibition of
ganglionic transmission in spontaneously hypertensive rats: Implications for
antihypertensive therapy with dopamine receptor agonists. Xth Scientific Meeting of the
International Society of Hypertension. Abst. #554, 1984.
62. Lokhandwala, M.F., Watkins, H. and Alkadhi, K.A.: Pharmacological analysis of the
action of SKF 82526 on cardiovascular dopamine receptors. IUPHAR 9th International
Congress of Pharmacology. Abst. #338, 1984.
63.
Alkadhi, K.A., Sabouni, M.H. and Lokhandwala, M.F.: Characterization of ganglionic
dopamine receptors in spontaneously hypertensive and normotensive rats. IUPHAR 9th
International Congress of Pharmacology Abst. #798, 1984.
64.
Sabouni, M.H. and Lokhandwala, M.F.: Differential inhibition of pre and
postganglionic cardiac sympathetic neurotransmission by selective DA1 and DA2
receptor agonists. IUPHAR 9th International Congress of Pharmacology. Abst. #797,
1984.
65.
Steenberg, M.L., Jandhyala, B.S. and Lokhandwala, M.F.: Effects of ouabain on [3H]norepinephrine release elicited during periarterial nerve stimulation in the perfused
kidneys of SHR and WKY rats. IUPHAR 9th International Congress of
Pharmacology. Abst. #1271P, 1984.
66.
Lokhandwala, M.F. and Steenberg, M.L.: Presynaptic (DA2) and post-synaptic
(DA1) dopamine receptors in the rat kidney. Fed. Proc. 44: 4902, 1985.
67.
Sengupta, S. and Lokhandwala, M.F.: Identification of dopamine receptor subtype(s)
involved in the hypotensive action of agonists by utilizing selective dopamine receptor
antagonists. Fed. Proc. 44: 7212, 1985.
68.
Sabouni, M.H., Alkadhi, K.A. and Lokhandwala, M.F.: Dopamine receptors in the
stellate ganglion of the dog. Fed. Proc. 44: 7213, 1985.
69.
Kavukondala, G.B., Jandhyala, B.S. and Lokhandwala, M.F.: Effects of ouabain on
the release of norepinephrine and vascular reactivity in the rat kidney. Fed. Proc.
44:7733, 1985.
70.
Lokhandwala, M. F., Sabouni, M. H. and Alkadhi, K. A.: Characterization of the
actions of felodopam in the dog hindlimb. Pharmacologist, 27: 579, 1985.
71.
Lokhandwala, M. F., Hamed, A. T. and Jandhyala, B. S.: Evaluation of the role of
alpha-1 and alpha-2 adrenoceptors in the neurogenic regulation of hindlimb vascular
tone in dogs. American Heart Association. Keystone, Colorado, February, 1986.
72.
Alkadhi, K. A., Sabouni, M. H. and Lokhandwala, M. F.: Activation of dopamine
DA-1 receptors by dopamine or fenoldopam causes an increase in levels in the renal
artery but not in the superior cervical ganglion of the rat, Fed. Proc. 45: 2386, 1986.
50
73.
Sabouni, M. H., Ansari, A. F., Alkadhi, K. A. and Lokhandwala, M. F.:
Electrophysiological and biochemical characterization of dopamine receptors in the
canine stellate ganglia. Fed. Proc. 45: 2387, 1986.
74.
Feldman, S. F., Weinheimer, A. J. and Lokhandwala, M. F.: Program for stimulation
of research careers in the pharmaceutical sciences. Amer. J. Pharm. Educ., 50: 295,
1986.
75.
DeFeo, M. L., Jadhav, A. L. and Lokhandwala, M. F.: Urinary dopamine and sodium
excretion during the development of hypertension in Dahl rats. Clin. Exp. Hyperten.,
A9: 1089, 1987.
76.
Sabouni, M. H., Alkadhi, K. A. and Lokhandwala, M. F.: Presynaptic and
postsynaptic dopamine receptors in rat superior cervical ganglion. Fed. Proc. 46: 126,
1987.
77.
Lokhandwala, M. F., DeFeo, M. L. and Jadhav, A. L.: Relationship between salt
consumption and urinary dopamine and sodium excretion during the development of
hypertension in Dahl rats. Fed. Proc. 46: 1199, 1987.
78.
DeFeo, M. L., Lokhandwala, M. F. and Jandhyala, B. S.: Activation of central
dopaminergic mechanisms with pergolide triggers the release of an endogenous
sodium-pump inhibitor and enhances vascular reactivity in anesthetized dogs. Fed.
Proc. 46: 1201, 1987.
79.
Watkins, H. O., Dlewati, A. and Lokhandwala, M. F.: Comparison of the effects of
dopamine receptor agonists fenoldopam and SK&F 85174 on hindlimb vascular
resistance in anesthetized dogs. Fed. Proc. 46: 6649, 1987.
80.
Dlewati, A., Watkins, H. O., Sabouni, M. H. and Lokhandwala, M. F.: Effects of
SK&F 85174, a dopamine receptor agonist, on pre and postganglionic sympathetic
neurotransmission to the heart. Fed. Proc. 46: 6650, 1987.
81.
Jadhav, A. L. and Lokhandwala, M. F.: A method for measuring the rate of dopamine
synthesis in the rat kidney cortex. Pharmacologist, 29: 532, 1987.
82.
Feldman, S. F., Weinheimer, A. J. and Lokhandwala, M. F.: Directed career
development program for pharmacy students. Amer. J. Pharm. Educ., 51: 315-316,
1987.
83.
Dlewati, A. and Lokhandwala, M. F.: Effects of intrarenal infusion of fenoldopam on
renal water and sodium excretion in pentobarbital-anesthetized dogs. FASEB J., 2:
1792, 1988.
Watkins, H. O., DeFeo, M. L., Dlewati, A. and Lokhandwala, M. F.: Effects of DA-1
receptor stimulation with fenoldopam on renal sodium excretion, plasma renin activity,
plasma aldosterone and atrial natriuretic factor in anesthetized dogs. FASEB J., 2:1793,
1988.
84.
85.
Hegde, S. S. and Lokhandwala, M. F.: Contribution of endogenous dopamine in the
diuretic and natriuretic response to acute volume expansion in rats. Hypertension,
12:65, 1988.
86.
Jadhav, A. L. and Lokhandwala, M. F.: Dietary sodium-induced changes in urinary
dopamine and electrolyte excretion in rats. Pharmacologist, 30:78.3, 1988.
51
87.
Dlewati, A. and Lokhandwala, M. F.: Influence of alpha and beta adrenoceptors
blockade on the renal effects of fenoldopam. Pharmacologist, 30:152.4, 1988.
88.
Hegde, S. S. and Lokhandwala, M. F.: Involvement of dopamine receptors in the
diuretic and natriuretic response to fenoldopam and acute volume expansion in
anesthetized rats. Pharmacologist, 30:152.5, 1988.
89.
Collier, W. L., Coppola, L., De Michele, M., Lokhandwala, M. F. and Amenta, F.:
Age-related changes of dopamine receptors in rat kidney. FASEB J., 3:2642, 1989.
90.
Watkins, H. O., Staniciu, D. and Lokhandwala, M. F.: Renal and endocrine effects of
the DA-2 receptor agonist quinpirole in anesthetized dogs. FASEB J., 3:3881, 1989.
91.
Dlewati, A. and Lokhandwala, M. F.: Dose-response analysis of hemodynamic and
renal effects of intravenous fenoldopam in pentobarbital-anesthetized dog. FASEB J.,
3:3882, 1989.
92.
Ricci, A., Amenta, F., Hegde, S. S. and Lokhandwala, M. F.: Autoradiographic
localization and functional characterization of renal dopamine receptors with
fenoldopam. FASEB J., 3:3883, 1989.
93.
Hegde, S. S. and Lokhandwala, M. F.: Activation of DA-1 but not DA-2 receptors by
endogenous dopamine contributes to the natriuretic response to acute volume expansion
in rats. FASEB J., 3:3884, 1989.
94.
Lokhandwala, M. F. and Hegde, S. S.: Renal dopamine receptors and natriuresis.
Proc. Soc. Exp. Biol. Med., 191:101, 1989.
95.
Daver, R. G., Lokhandwala, M. F. and Jadhav, A. L.: Involvement of kidney
dopamine and plasma atrial natriuretic peptide in the natriuretic response to high
sodium intake. Pharmacologists, 31:377, 1989.
96.
Vyas, S. J. and Lokhandwala, M. F.: Role of tubular dopamine-1 receptors in the
natriuretic and diuretic response to dopexamine. Pharmacologist, 31:378, 1989.
97.
Azad, A. K., Vyas, S. J., Hegde, S. S. and Lokhandwala, M. F.: Dopamine-1 but not
dopamine-2 receptor agonists cause natriuresis via activation of DA receptors. Proc.
Soc. Exp. Biol. Med., 193: 246, 1990.
98.
Vyas, S. J. and Lokhandwala, M. F.: Involvement of tubular dopamine-1 receptors in
the natriuretic and diuretic response to dopexamine in rats. Proc. Soc. Exp. Biol. Med.,
193: 246, 1990.
99.
Lokhandwala, M. F., Hegde, S. S., Ricci, A., Vega, J. and Amenta, F.: Role of renal
dopamine and DA-1 receptors in the natriuretic and diuretic response to atrial
natriuretic factor. Kidney Int. 37: 341, 1990.
100. Lokhandwala, M. F. and Hegde, S. S.: Renal dopamine receptors and natriuresis:
Characterization of receptors and signal transduction systems. J. Auton. Pharmacol.,
10: 5-6, 1990.
52
101. Vyas, S. J., Ricci, A., Amenta, F. and Lokhandwala, M. F.: Autoradiographic
evidence for the role of dopamine-1 receptors in the natriuretic response to
dopexamine. FASEB J. 4: 1977, 1990.
102. Watkins, H. O., Etumnu, P., Hegde, S. S. and Lokhandwala, M. F.: Renal effects of
dopamine-2 receptor agonist bromocriptine in dogs. FASEB J. 4: 1978, 1990.
103. Hegde, S. S., Ricci, A., Vega, J., Amenta, F. and Lokhandwala, M. F.: Evidence for
the role of endogenous renal dopamine and DA-1 receptors in the renal effects of atrial
natriuretic factor. Europ. J. Pharmacol., 183: 1153, 1990.
104. Jadhav, A. L. and Lokhandwala, M. F.: Interactions between atrial natriuretic
peptides and renal dopamine during high sodium intake. Europ. J. Pharmacol., 183:
1051, 1990.
105. Ricci, A., Napoleone, P., Amenta, F., Vyas, S. and Lokhandwala, M. F.: Anatomical
localization of the binding and functional characterization of responses to dopexamine
hydrochloride, a DA-1 and ß2-adrenoceptor agonist in the rat mesenteric vasculature.
J. Auton. Pharmacol., 10 (Suppl 1):S129, 1990.
106. Jadhav, A. L., Lokhandwala, M. F., Ricci, A. and Amenta, F.: Alterations in kidney
dopamine production and dopamine receptors during increased sodium intake. J.
Auton. Pharmacol., 10 (Suppl 1): S130, 1990.
107. Hegde, S. S. and Lokhandwala, M. F.: Stimulation of renal dopamine production
during acute volume expansion requires the presence of intact vagi but not renal nerves.
J. Auton. Pharmacol., 10 (Suppl 1): S130, 1990.
108. Chen, C. J. and Lokhandwala, M. F.: A defect in renal tubular dopamine DA-1
receptor function causes diminished natriuresis to volume expansion in spontaneously
hypertensive rats. FASEB J., 5: 1705, 1991.
109. Vyas, S. J., Eichberg, J. and Lokhandwala, M. F.: Identification of receptors involved
in dopamine induced activation of phospholipase-C in rat kidney. FASEB J., 5: 4038,
1991.
110. Lokhandwala, M. F. and Chen, C. J.: Diminished natriuresis to volume expansion in
spontaneously hypertensive rats is due to an impairment of tubular dopamine DA-1
receptor function. Hypertension, 17: 410, 1991.
111. Vyas, S. J., Eichberg, J. and Lokhandwala, M. F.: Modulation by dopamine of renal
phospholipase-C activity after increase in sodum intake. Hypertension, 18:405, 1991.
112. Chen,C.J., Vyas, S. J., Beach, R. E., Eichberg, J. and Lokhandwala, M. F. :
Diminished natriuresis to dopamine in spontaneously hypertensive rats is due to a
defect in phospholipase-C mediated inhibition of Na+-K+-ATPase. J. Amer. Soc.
Nephrol., 2:472, 1991.
113. Vyas,S.J., and Lokhandwala, M. F.: Identification of tubular and hemodynamic
components in the natriuretic response to dopamine. FASEB Journal, 6: 5316, 1992.
114. Chen, C.J., and Lokhandwala, M.F.: Dopamine-induced inhibition of Na+,K+ATPase in renal proximal tubule is mediated by DA-1 receptor activation. FASEB
Journal, 6: 5317,1992.
53
115. Sakamoto,T., and Lokhandwala, M.F.: Lack of renal dopamine production during
acute volume expansion in prehypertensive Dahl rats. J. Hpertension, 10 (Suppl.4):
S119, 1992.
116. Chen, C.J., and Lokhandwala, M.F.: Dopamine DA-1 receptor but not DA-2 receptor
is involved in DA-mediated inhibition of Na,K-ATPase in renal proximal tubule cells.
J. Hypertension, 10 (Suppl.4): S119, 1992.
117. Chen, C.J., and Lokhandwala, M.F.: Identification of site(s) of defect in DA-1
receptor coupled phospholipase-C signaling pathway in the renal proximal tubule of
SHR. Pharmacologist, 34: 46, 1992.
118. Jadhav, A.L., Liu, Q., and Lokhandwala, M.F.: Effect of volume and Na+
disturbances on renal cortical DA1 receptor affinity and density. Pharmacologist, 34:
325, 1992.
119. Chen, C.J. and Lokhandwala, M.F.: Defective dopamine (DA) DA-1 receptor coupled
signaling mechanisms cause loss of DA-induced inhibition of Na+,K+-ATPase in renal
proximal tubule of SHR. J.Amer.Soc.Nephrol. 3:517,1992.
120. Jacinto, S.M., Lokhandwala, M.F. and Jandhyala, B.S.: Comparative effects of
dopexamine, dobutamine and prenalterol on free radical mediated toxicity induced by
xanthine plus xanthine oxidase. FASEB Journal, 7: 2462, 1993.
121. Chen, C. J. and Lokhandwala, M. F.: Dopamine-induced inhibition of Na,K-ATPase
activity in renal proximal tubule involves DA-1 receptor coupled phospholipase-C
signalling pathway. FASEB Journal, 7: 2624, 1993.
122. Jandhyala, P., Watkins, H. O., Chen, C. J. and Lokhandwala, M. F.: Intrarenal
prostaglandins are not involved in the diuretic and natriuretic response to DA-1
receptor agonist, fenoldopam. FASEB Journal, 7: 1434, 1993.
123. Gopalakrishnan, S .M., Chen, C. J. and Lokhandwala, M. F.: Identification of α1Adrenoceptor subtype(s) mediating norepinephrine-induced stimulation of sodium
pump in renal proximal tubules. Hypertension, 22, 443, 1993.
124. Gopalakrishnan, S. M., Chen, C. J. and Lokhandwala, M. F.: α1-Adrenoceptor
subtypes involved in inositol trisphosphate and Na,K-ATPase stimulation in renal
proximal tubules. J. Amer. Soc. Nephrol. 4:486, 1993.
125. Venkatakrishnan, U., Chen, C. J. and Lokhandwala, M. F.: Involvement of kidney
nitric oxide in the natriuretic response to dopamine-1 receptor stimulation. J. Amer.
Soc. Nephrol. 4:571, 1993.
126. Chen, C. J., Venkatakrishnan, U. and Lokhandwala, M. F.: Antinatriuretic response to
intrarenally infused phenylephrine is mediated via α1-Adrenoceptor activation. J.
Amer. Soc. Nephrol. 4:576, 1993.
127. Lokhandwala, M.F., Gopalakrishnan, S.M. and Chen, C.J.: α1-Adrenoceptor subtypes
involved in norepinephrine-induced stimulation of Na,K-ATPase activity in renal
proximal tubules. J. Autonomic Pharmacol. 14: 21, 1994.
54
128. Chen, C.J. and Lokhandwala, M.F.: Noradrenergic modulation of Na,K-ATPase
activity in the renal proximal tubules of spontaneously hypertensive rats. Clin. Exp.
Pharmacol. Physiol. Supplement 1: S29, 1994.
129. Kansra,V., Chen, C. J. and Lokhandwala, M. F.: Dopamine fails to stimulate protein
kinase C activity in renal proximal tubules of spontaneously hypertensive rats. FASEB
Journal., 9: 310, 1995.
130. Jacinto, S. M., Lokhandwala, M. F. and Jandhyala, B. S.: Lipid peroxidation and
respiratory depression are primary factors responsible for the lethal toxicity induced by
oxygen free radicals in anesthetized rats. FASEB Journal, 9: 2452, 1995.
131. Pedemonte,C.H., Pressley,T.A. and Lokhandwala,M.F.: Amino acids located in the
amino terminal end of the rat Na-pump α-subunit are essential for the stimulation by
protein kinase C. Biophysical J. 70: A138, 1996.
132. Lokhandwala, M.F., Kansra, V. and Hussain, T.: Dopamine and phospholipase A2 in
the inhibition of sodium pump in renal proximal tubules of spontaneously hypertensive
rats. J. Hypertension, 14(Suppl 1):S40, 1996.
133. Hussain, T. and Lokhandwala, M.F.: Dopamine-1 receptor-Gq/11 protein coupling in
renal basolateral membrane and reduced Gq/11 α in spontaneously hypertensive rats.
J. Hypertension, 14(Suppl 1):S131, 1996.
134. Bharatula, M., Hussain, T. and Lokhandwala, M. F.: Role of Gs and Gi proteins in the
biphasic response of proximal tubular sodium pump to angiotensin II. J. Amer. Soc.
Nephrol. 7: 1627, 1996.
135. Hussain, T., Abdul-Wahab, R., Bharatula, M. and Lokhandwala, M. F.: Dopamine-2
receptor modulates angiotensin II response on renal Na,K-ATPase through
heterologous desensitization. J. Amer. Soc. Nephrol. 7: 1678, 1996.
136. Kansra, V., Hussain, T. and Lokhandwala, M. F.: Alteration in dopamine-1 receptor
and G-proteins in Fischer 344 old rat kidney. J. Amer. Soc. Nephrol. 7: 1679, 1996.
137. Hussain, T. and Lokhandwala, M. F.: Increased expression of D1A dopamine receptor
protein in renal proximal tubular basolateral membranes from spontaneously
hypertensive rats. J. Amer. Soc. Nephrol. 8: 300A, 1997.
138. Hussain, T., Abdul-Wahab, R. and Lokhandwala, M. F.: Bromocriptine, a D2-like
receptor agonist regulates dopamine-mediated inhibition of Na,K-ATPase in rat renal
proximal tubules: The role of G proteins. J. Amer. Soc. Nephrol. 8: 439A, 1997.
139. Hussain, T., Kotak, D. D., Abdul-Wahab, R. and Lokhandwala, M. F.: A decrease in
dopamine D1-like receptors contributes to reduced inhibition of Na,K-ATPase activity
in the proximal tubules of obese hypertensive rats. FASEB Journal, 12: 557, 1998.
140. Lokhandwala, M. F., Kotak, D. D. and Hussain, T.: Defective dopamine receptor
signal transduction in renal proximal tubules of obese hypertensive rats. J.
Hypertension, 16: S72, 1998.
141. Hussain, T., Abdul-Wahab, R., Kotak, D. and Lokhandwala, M. F.: Dopamine
receptor preactivation causes an increase in Gs protein and a decrease in [3H]
angiotensin II binding sites in proximal tubules. J. Hypertension, 16: S125, 1998.
55
142. Hussain, T., Beheray, S.A., Kotak, D.K., Abdul-Wahab, R. and Lokhandwala, M.F.:
Downregulation of dopamine receptors and G protein function in renal proximal
tubules of obese Zucker rats. J. Amer. Soc. Nephrol. 9: A2045, 1998.
143. Beheray, S.A., Hussain, T. and Lokhandwala, M.F.: Altered expression and function
of G proteins in proximal tubules of old Fisher 344 rats. J. Amer. Soc. Nephrol. 9:
A2139, 1998.
144. Becker, M.L., Hussain, T. and Lokhandwala, M.F.: Increased c-AMP inhibition by
angiotensin II in the proximal tubules of obese Zucker rats: Evidence for increased AT
1 receptor sensitivity in the obese rats. FASEB Journal, 13: A790, 1999.
145. Beheray, S.A., Hussain, T. and Lokhandwala, M.F.: Dopamine stimulates protein
kinase A through the activation of D1-like dopamine receptors in the renal proximal
tubules. FASEB Journal, 13: A791, 1999.
146. Beheray, S.A., Hussain, T. and Lokhandwala, M.F.: Altered modulation of G proteins
by hormones and peptides in the renal proximal tubules of adult and old Fischer 344
rats. FASEB Journal, 13: A798, 1999.
147. Narkar, V., Hussain, T., Pedemonte, C. and Lokhandwala, M.: Dopamine activates
p42/44 MAP Kinase and promotes mitogenesis in opossum kidney cells. FASEB
Journal, 13: LB118, 1999.
148. Hussain, T., Beheray, S. A. and Lokhandwala, M. F.: Defective dopamine receptor G
protein function contributes to reduced dopamine-mediated inhibition of Na,K-ATPase
in proximal tubules of obese Zucker rats. Amer. J. Hypertension, 12: 68A, 1999.
149. Lokhandwala, M. F.: Dopamine and blood pressure regulation. Fundamental &
Clinical Pharmacol. 13 (Suppl.1): 60s, 1999.
150. Hussain,T., Kotak, D. K., Abdul-Wahab, R. and Lokhandwala, M. F.: Dopamine
receptor signal transduction in renal proximal tubules of obese Zucker rats. Clin. Exp.
Pharmacol. Physiol. 26 (Suppl): S55, 1999.
151. Beheray, S., Hussain, T. and Lokhandwala, M. F.: Altered expression and stimulation
of G-proteins by hormones and peptides in renal proximal tubules old Fischer 344 rats.
Clin. Exp. Pharmacol. Physiol. 26 (Suppl): S56, 1999.
152. Vieira-Coelho, M. A., Hussain, T., Soares-da-Silva, P. and Lokhandwala, M. F.:
Effect of aging and sodium diet on intestinal Na, K-ATPase activity and dopaminergic
tonus in Fischer 344 rats. Clin. Exp. Pharmacol. Physiol. 26 ( Suppl ): S62, 1999.
153. Becker, M. L., Lokhandwala, M. F. and Hussain,T.: Increased angiotensin II
stimulation of Na,H-exchanger activity in the proximal tubules of obese Zucker
hypertensive rats via a cAMP dependent pathway. J. Amer. Soc. Nephrol. 10: A2272,
1999.
154. Beheray, S. A., Kansra, V., Hussain, T. and Lokhandwala, M. F.: Diminished
natriuretic response to dopamine in old rats: Evidence of impaired dopamine receptor
signaling pathway inhibiting the Na,H-exchanger. J. Amer. Soc. Nephrol. 10: A2273,
1999.
56
155. Narkar, V., Hussain, T., Pedemonte, C, and Lokhandwala, M. F.: Dopamine D2-like
receptor stimulation causes activation of p44/42 MAP kinase pathway and promotes
mitogenesis in opossum kidney cells. J. Amer. Soc. Nephrol. 10: A2516, 1999.
156. Asghar, M., Hussain, T. and Lokhandwala, M. F.: Dopamine D1-like receptor
activation causes phosphorylation of alpha-subunit of Na,K-ATPase in the proximal
tubules via protein kinase C pathway. FASEB J. 14: A1549, 2001.
157. Narkar, V. A., Hussin, T. and Lokhandwala, M. F.: Dopamine D2-like (D2 and D4)
receptor activation leads to mitogenesis via p44/42 MAPK stimulation in Opposum
kidney cells. FASEB J. 14: A1550, 2000.
158. Hussain, T., Becker, M., Beheray, S. and Lokhandwala, M.F.: Dopamine-mediated
inhibition of Na,H-exchanger in proximal tubules of obese Zucker rats. J.
Hypertension 18:P40.20, 2000.
159. Narkar, V. A., Hussain, T. and Lokhandwala, M.F.: Activation of Dopamine D2 and
D3 receptors causes stimulation of Na+,K+,ATPase via a P44/42 MAPK pathway in
renal proximal tubules. J. Amer. Soc. Nephrol. 11: A2235, 2000.
160. Asghar, M., Hussain, T. and Lokhandwala, M.F.: Defective renal dopamine response
in old rats is due to elevated basal protein kinase C activity and phosphorylation state of
Na,K-ATPase. J. Amer. Soc. Nephrol. 11: A2303, 2000.
161. Narkar, V.A., Hussain, T., Pedemonte, C. and Lokhandwala, M.F.: Evidence for
expression of dopamine D2 and D4 receptors in opossum kidney cells and the role of
D2 receptors in mitogenesis. J. Amer. Soc. Nephrol. 11: A2342, 2000.
162. Hussain, T., Lokhandwala, M. F., Henegar, J., Henegar, L., & Hall, J. E.: Increased
Expression of Na,H-Exchanger and Na,K-ATPase in Renal Cortex of Obese Dogs Fed
a High Fat Diet. FASEB J. 15:A134, 2001.
163. Narkar, V.A., Hussain, T. and Lokhandwala, M.F.: Activation of D2 and D3
Receptors Causes Stimulation of Na+,K+, ATPase Via a Tyrosine Kinase-p44/42
MAPK Pathway in Rat Proximal Tubules. FASEB J. 15:A571, 2001.
164. Asghar, M., Hussain, T. and Lokhandwala, M.F.: Hyperphosphorylation of both
dopamine D1A receptor and Na,K-ATPase lead to defective dopamine response in old
rats. FASEB J. 15:A929, 2001.
165. Menezes, M., Hussain, T. and Lokhandwala, M.F.: Identification of D2-Like
Dopamine Receptors in Rat Renal Proximal Tubular Brushborder and Basolateral
Membranes: Role in the Inhibition of cAMP. J. Amer. Soc. Nephrol. 12: A2977,
2001.
166. Hussain, T., Menezes, M. and Lokhandwala, M.F.: Defective D1-Like Dopamine
Receptor Stimulation of Inositol Triphosphate (IP3) and Inhibition of Na,K-ATPase by
Arachidonic Acid in the Proximal Tubules of Old Fischer 344 Rats. J. Amer. Soc.
Nephrol. 12: A3032, 2001.
167. Asghar, M., Hussain, T. and Lokhandwala, M.F.: Over-Expression pf PKC-β1 and -δ
Isoforms in Renal Proximal Tubules Leads to Increased Basal Phosphorylation and
Diminished Inhibition on Na,K-ATPase by Dopamine in Old Rats. J. Amer. Soc.
Nephrol. 12: A3050, 2001.
57
168. Narkar, V.A., Hussain, T. and Lokhandwala, M.F.: Dopamine D2-Like Receptor
Activation Causes Stimulation of Na+,K+,ATPase via Tyrosine Phosphorylation and
Recruitment of Na+,K+,ATPase a1 Subunit in Proximal Tubules. J. Amer. Soc.
Nephrol. 12: A3108, 2001.
169. Hussain, T. and Lokhandwala, M. F.: Defective D1-like receptor signaling contributes
to the inability of dopamine to inhibit sodium transporters in the proximal tubules of
obese Zucker rats. Int J Obesity 25: S26, 2001.
170. Trivedi, M., Hussain, T. and Lokhandwala, M.F.: Dopamine D1-Like Receptor
Recruitment in Renal Proximal Tubules of Sprague Dawley Rats. FASEB J. 16:A197,
2002.
171. Asghar, M., Hussain, T. and Lokhandwala, M.F.: Increased Phosphorylation and
Down Regulation of D1A Receptor Contribute to the Defective Dopamine Response in
Old Fischer 344 Rats. FASEB J. 16:A576, 2002.
172. Amenta, F., Hussain, T., Lokhandwala, M.F., Mignini, F., Ricci, A. and Tayebati, S.
K.: Changes with Aging in Dopamine Receptor Expression in the Rat Mesenteric
Vasculature. FASEB J. 16:A933, 2002.
173. Umrani, D. N., Hussain, T. and Lokhandwala, M.F.: Rosiglitazone Treatment
Restores Renal Dopamine Receptor Function and Lowers Blood Pressure in Obese
Zucker Rats. Amer. J Hypertension, 15:188A, 2002.
174. Banday, A. A., Asghar, M., Hussain, T. and Lokhandwala, M. F.: Insulin
Downregulates D1 Receptor Function in Primary Proximal Tubular Epitheal Cells from
Rat Kidney. J. Amer. Soc. Nephrol. 13: 289A, 2002.
175. Trivedi, M., Hussain, T. and Lokhandwala, M. F.: Newly Recruited D1A Receptors
by Dopamine are Involved in the Inhibition of Na,K-ATPase in Renal Proximal
Tubules. J. Amer. Soc. Nephrol. 13: 740A, 2002.
176. Lokhandwala, M. F., Banday, A., Umrani, D. and Hussain, T.: Rosiglitazone
Treatment Reverses Renal Dopamine D1- Receptor Downregulation, Normalizes D1
Receptor Function and Lowers Blood Pressure in Obese Zucker Rats. Hypertension, 40:
386, 2002.
177. Lokhandwala, M. F., Asghar, M. and Hussain, T.: Prevention of oxidative stressinduced elevation of prtein kinase C activity with α-lipoic acid in the kidneys of old
rats. Free Rad. Biol. Med. 33: S354, 2002.
178. Hussain, T., Umrani, D. and Lokhandwala, M.F.: Renal dopamine receptor function in
hyperinsulinemic rats. Clin. Exp. Hypertension, 25: 60, 2003.
179. Lokhandwala, M.F., Asghar, M. and Hussain, T.: Age-related changes in renal
dopamine receptor function. Clin. Exp. Hypertension, 25: 64, 2003.
180. Khera, A. and Lokhandwala, M.F.: Diminished diuretic and natriuretic response to
dopamine D1-like receptor agonist, SKF-38393 in obese Zucker rats. FASEB J. 17,
386.7, 2003
58
181. Trivedi, M., Hussian, T. and Lokhandwala, M.F.: Newly recruited dopamine D1A
receptor are functional and involved in the inhibition of Na,K-ATPase by dopamine in
renal proximal tubules. FASEB J. 17, 393.6, 2003.
182. Banday, A. A., Asghar, M., Hussain, T. and Lokhandwala, M. F.: Insulin-mediated
uncoupling of dopamine D1 receptor fropm Gprotein as a mechanism for diminished
inhibition of renal Na,K-ATPase by dopamine in obese Zucker rats. Amer. J.
Hypertension, 16: 19A, 2003.
183. Trivedi, M., Khera, A., Hussain, T. and Lokhandwala, M.F.: Improvement in insulin
sensitivity with rosiglitazone restores recruitment, G-protein coupling and function of
renal dopamine D1A receptors in obese Zucker rats. Hypertension, 42: 396, 2003.
184. Khera, A., Banday, A. and Lokhandwala, M.F.: Reduced dopamine D1-like receptor
expression and function in stretozotocin-induced diabetic rats. Hypertension, 42: 421,
2003.
185. Banday, A. A., Hussain, T. and Lokhandwala, M.F.: Impaired renal dopamine D1receptor function is induced by circulating factors and is not inherited in obese Zucker
rats. Hypertension, 42: 423, 2003.
186. Banday, A.A., Hussain, T. and Lokhandwala, M.F.: Impaired renal dopamine D1
receptor function is aquired and not inherited in obese Zucker rats. J. Amer. Soc.
Nephrol. 14:549A, 2003.
187. Banday, A.A., Hussain, T. and Lokhandwala, M.F.: Free fatty acid-induced
uncoupling of D1 receptors from G proteins contributes to diminished inhibition of
renal Na, K- ATPase by dopamine. J. Amer. Soc. Nephrol. 14: 775A, 2003.
188. Asghar, M. and Lokhandwala, M.F.: Antioxidants reduce oxidative stress, normalize
PKC activity and reverse dopamine D1 receptor downregulation in proximal tubules of
old rats. Free Rad. Biol. Med. 35: S31, 2003.
189. Banday, A. A. and Lokhandwala, M.F.: Antioxidant tempol restores renal dopamine
D1 receptor function in obese Zucker rats. Free Red. Biol. Med. 35, S31, 2003.
190. Marwaha, A., Banday, A. and Lokhandwala, M.F.: Impaired renal dopamine D1
receptor function in streptozotocin-induced diabetic rats. FASEB J. 18: 395.7, 2004.
191. Trivedi, M. and Lokhandwala, M.F.: Rosiglitazone treatment restores D1A receptor
signaling by correcting its hyperphosphorylation state in proximal tubules of obese
Zucker rats. FASEB J. 18: 399.18, 2004.
192. Banday, A. A., Marwaha, A. and Lokhandwala M.F.: Tempol reduces oxidative
stress, improves insulin sensitivity, and restores renal dopamine D1 receptor-G protein
coupling and function in obese Zucher rats. Amer. J. Hypertension, 17: 214A, 2004.
193. Banday, A. A., Marwaha, A. and Lokhandwala, M. F.: Tempol improves insulin
sensitivity and restores renal dopamine D1 receptor-G protein coupling and function in
obese Zucker rats. Hypertension, 44: 531, 2004.
194. Lokhandwala, M. F. and Trivedi, M.: Insulin sensitizer, rosiglitazone, retores coupling
of D1A receptors to Gs-proteins by reducing GRK expression and
59
hyperphosphorylation of D1A receptors in obese Zucker rats. Hypertension, 44: 531,
2004.
195. Banday, A. A., Marwaha, A. and Lokhandwala, M. F.: Hyperglycemia-induced
oxidative stress impairs renal dopamine D1 receptor function via protein kinase C
activation and G protein coupled receptor kinase 2 translocation. Hypertension, 44:
559, 2004.
196. Asghar, M., Banday, A.A., Fardoun, R. and Lokhandwala, M.F.: Hydrogen Peroxide
causes uncoupling of dopamine D1 receptors from G-proteins via a mechanism
involving PKC and GRK2 in cell cultures from renal proximal tubules. Free Rad. Biol.
Med. 37: S60, 2004
197. Banday, A.A., Marwaha, A. and Lokhandwala, M.F.: Oxidative stress in
hyperglycemic rats causes renal dopamine D1 receptor hyperphosphorylation via PKC
activation and GRK2 translocation. Free Rad. Biol. Med. 37: S67, 2004.
198. Banday, A. and Lokhandwala, M. F.: Glucose increases oxidative stress and protein
kinase C activity resulting in hyperphosphorylation of dopamind D1 receptor,
uncoupling from G proteins and loss of agonist induced response. J. Amer. Soc.
Nephrol. 15: 445A, 2004.
199. Marwaha, A. and Lokhandwala, M. F.: Oxidative stress contributes to reduced renal
dopamine D1 receptor function in hyperglycemic rats. FASEB Journal, 19: 90.2, 2005.
200. Asghar, M. and Lokhandwala, M. F.: Lowering of oxidative stress by tempol leads to
a decrease in age-associated increase in insulin resistance in Fischer 344 rats. Free Rad.
Biol. Med. 39: S30, 2005.
201. Asghar, M., Fardoun, R.Z., Banday, A.A. and Lokhandwala, M.F.: Oxidative stressinduced activation of nuclear transcription facter NFkB and G-protein coupled receptor
kinase 2 causes dopamine D1 receptor G-protein uncoupling in renal proximal tubules
of old rats. J. Amer. Soc. Nephrol. 16, 374A, 2005.
202. Asghar, M., Zeyssig, R., Monjok, E., Kouamou, G., Ohia, S.E., Lokhandwala, M.F.
and Bagchi, D.: Effect of a novel hydroxycitric acid extract (HCA-SX) on oxidative
stress, insulin resistance and brain serotonin levels in obese Zucker rats. FASEB J. 20:
655.4, 2006.
203. Fardoun, R.Z., Asghar, M. and Lokhandwala, M.F.: Oxidative stress causes activation
of NF-kB in renal proximal tubules of spargue dawley rats. FASEB J. 20: 709.8, 2006.
204. Banday, A.A. and Lokhandwala, M.F.: Oxidative stress induced renal D1 receptor
dysfunction causes salt sensitive hypertension in spague dawley rats. FASEB J. 20:
743.11, 2006.
205. Asghar, M., Fardoun, R. and Lokhandwala, M.F.: Oxidative stress and age-related
decline in renal dopamine D1 receptor function. Free Radical Research, 40: S84, 2006.
206. Banday, A.A. and Lokhandwala, M.F.: Impaired renal dopamine D1 receptor function
contributes to oxidative stress mediated hypertension. Free Radical Research, 40:S152,
2006.
60
207. Banday, A.A., Fazili, F.R. and Lokhandwala, M.F.: Chronic insulin treatment
phosphorylates ά1 Na, K-ATPase subunit at serine 11/18 and reduces its activity
involving phophotidylinositol-3-kinase dependent atypical Protein Kinase C ξ/λ
activation. J Am Soc Nephrol 17: 296A, 2006.
208. Banday, A.A., Fasili, F.R. and Lokhandwala, M.F.: G-protein coupled receptor kinase
2 mediates high glucose induced renal dopamine D1 receptor desensitization by
interacting with Gάq/11. J Am Soc Nephrol 17: 365A, 2006.
209. Banday, A.A., Fazili, F.R. and Lokhandwala, M.F.: Oxidative stress induced renal
dopamine D1 receptor dysfunction involves NF-kB and protein kinase C activation. J
Am Soc Nephrol 17: 450A, 2006.
210. Banday, A.A., Fazili, F.R. and Lokhandwala, M.F.: ERK1/2 and G-protein coupled
receptor kinase 2 are required for insulin induced heterologous dopamine D1 receptor
desensitization in renal epithelial cells. J Am Soc Nephrol 17: 594A, 2006.
211. Fardoun, R.Z., Asghar, M. and Lokhandwala, M.F.: NF-kB contributes to oxidative
stress-induced defective renal dopamine D1 receptor signaling in renal proximal
tubules of Sprague Dawley rats. J Am Soc Nephrol 17: 603A, 2006.
212. Liza, G., Asghar, M. and Lokhandwala, M.F.: Exercise reduces oxidative stress and
inflammation and increases D1 receptor numbers and G-protein activation in renal
proximal tubules of old rats. J Am Soc Nephrol 17: 603A, 2006.
213. Banday, A.A., Muhammad, A.B. and Lokhandwala, M.F.: Mechanisms of oxidative
stress induced increase in salt sensitivity and development of hypertension in Spraguedawley rats. Hypertension, 48: e56, 2006.
214. Lokhandwala, M.F., Marwaha, A., Trivedi, M. and Banday, A.A.: Oxidative Stress
and renal dopamine D1 receptor function in experimental diabetes. Clin Exp
Hypertension, 29: 223, 2007.
215. George, L., Asghar, M., and Lokhandwala, M.F. Exercise Stimulates Transcription Factors
(Nrf2 & NF-κB), Increases Antioxidant Defenses, Decreases Oxidative Stress, and Restores
Renal Dopamine D1 Receptor Function in Aging. FASEB J 22, 1159.6, 2008.
216. Lokhandwala, M.F., Banday, A.A., Bhatt, S. and Javkhedkar, A.: Oxidative stress and
transcriptional regulation of angiotensin AT1 receptors in hypertension. Physiol. Res. 57: 54P,
2008.
217. Banday, A.A. and Lokhandwala, M.F.: Antioxidant mediated Nrf2 activation blocks NFkB
stimulation and prevents angiotensin AT1 receptor upregulation and hypertension during
oxidative stress. Hypertension, 52: e58, 2008.
218. Banday, A.A. and Lokhandwala, M.F.: Oxidative stress-induced renal angiotensin AT1
receptor upregulation causes increased stimulation of sodium transporters in hypertension.
Hyppertension, 52: e59, 2008.
219. Banday, A.A. and Lokhandwala, M.F.: Role of Nrf2 in prevention of renal angiotensin AT1
receptor upregulation and hypertension during oxidative stress. J. Amer. Soc. Nephrol. 19: 67A,
2008.
61
220. George, L., Lokhandwala, M.F. and Asghar, M.: Role of NFkB and Nrf2 in exercise-induced
restoration of renal dopamine D1 receptor function in aging. J. Amer. Soc. Nephrol. 19: 139A,
2008.
221. Asghar, M. and Lokhandwala, M.F.: Inflammation produced by lipopolysaccharide
downregulates renal Nrf2, compromises renal D1 receptor function and increases blood
pressure during high salt intake. J. Amer. Soc. Nephrol. 19: 140A, 2008.
222. Banday, A. A. and Lokhandwala, M. F.: Loss of biphasic effect on renal Na/KATPase by angiotensin II involves defective regulation of AT1 rec
eptor-NO-cGMP signaling during oxidative stress. J. Amer. Soc. Nephrol. 19: 377A,
2008.
223. George, L., Asghar, M., and Lokhandwala, M.F. Exercise Stimulates Transcription
Factors (Nrf2 & NF-κB), Increases Antioxidant Defenses, Decreases Oxidative
Stress, and Restores Renal Dopamine D1 Receptor Function in Aging. FASEB J 22,
1159.6, 2008.
224. Banday, A. A. and Lokhandwla, M. F.: Antioxidant-mediated Nrf2 activation
prevents AT1 receptor upregulation, endothelial dysfunction and hypertension by
abolishing NFkB activation during oxidative stress, J. Clin. Hypertension, 11:A2,
2009.
225. Bhatt, S., Lokhandwala, M.F. and Banday, A.A.: Vascular and Not Systemic
Oxidative Stress Precedes Development of Hypertension and Is Associated with
NFκB Activation and AT1 Receptor Upregulation. 63rd Annual High Blood
Pressure Research Conference 2009 Hypertension.2009; 54: e26-e127 (P261)
226. Bhatt, S., Lokhandwala, M.F. and Banday, A.A.: Early Chronic Resveratrol
Treatment Reduces Blood Pressure and Vasoconstriction and Improves
Endothelium-Dependent Vasorelaxations by Lowering Oxidative Stress in
Spontaneously Hypertensive Rats. 63rd Annual High Blood Pressure Research
Conference 2009 Hypertension.2009; 54: e26-e127 (P268)
227. Bhatt, S., Banday, A.A. and Lokhandwala M.F.: Vascular oxidative stress, NFκB activation
and AT1 Receptor upregulation precede the development of hypertension in Spontaneously
Hypertensive Rats (SHR) FASEB J. 2009 23:LB53 (Experimental Biology 2009)
228. Amenta, F., Bhatt, S., Nwankwo, I.E., Muhammad, A.B., Ricci,A., Tayebati,S.K., Tomassoni,
D. and Lokhandwala, M.F.: Microanatomical Changes In The Brain Of Obese Zucker Rats:
A Model Of Metabolic Syndrome 6th International Meeting on Vascular Dementia, Spain,
2009. (#327)
229. Javkhedkar, A., Lokhandwala, M.F. and Banday, A.A.: Higher renal AT1 receptor affinity
exaggerates Ang II induced Na/K-ATPase stimulation in spontaneously hypertensive rats.
FASEB J. 24: LB707, 2010.
62
230. Banday, A.A. and Lokhandwala, M.F.: Oxidative stress causes renal AT1 receptor
upregulation, NHE3 overstimulation and hypertension. Hypertension, 56: e117, 2010.
231. Bhatt, S., Lokhandwala, M.F. and Banday, A.A.: Oxidative stress via nuclear factor kappa B
causes vascular angiotensin type 1 receptor upregulation and contributes to development of
hypertension in SHR. Hypertension, 56: e154, 2010.
232. Javkhedkar, A., Lokhandwala, M.F. and Banday, A.A.: Oxidative stress impairs renal nitric
oxide signaling and ang II mediated biphasic Na/K-ATPase regulation in spontaneously
hypertensive rats. Hypertension, 52: e164, 2010.
233. Chugh, G., Lokhandwala, M.F. and Asghar, M.: Age-associated oxidative stress alters renal
D1 and AT1 receptor functions and increases blodd pressure in old Fischer 344 X Brown
Norway F1 rats. Hypertension, 56: e164, 2010.
63